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Prescribing treatment based on clinical assessment in the absence ofconfirmatory tests .. 
Pallor 
Refers to paleness of skin caused by illnesses such as anaemia. 
Sensitivity 
Ability ofa test to detect cases with the disease or outcome of interest 
Specificity 
The ability of a test to detect cases without the disease or outcome of interest. 
Pre-test probability . 
The probability that a given case has the disease of interest before a diagnostic test is 
performed. 
Post-test probability 
The probability that a given patient has the disease of interest after a diagnostic test is 
performed. 
Likelihood ratio 
The probability that a given test result would be expected in a patient with the targeted 
outcome compared with the probability that the same result would be expected in patient 
without the targeted outcome. 
Accuracy 
Ability ofa test to correctly identify positive and negative cases in any given sample or 
population (Sum of true positives and true negative divided by total cases tested). 
Gini CoeffiCient 
Standard measure of the relative inequality in a population on a scale of 0 to 1. Where 1 
indicates perfect equality and 0 represents perfect inequality. 
Fever 
Temperature greater or equal to 37.SoC. 
Asymptomatic 















Malaria is a major public health problem in Zambia accounting for more than 3 million 
clinical cases and about 33,000 deaths annually. Artemether-Iumefantrine, (a relatively 
expensive drug) is being used for first line treatment of uncomplicated malaria. However, 
diagnostic capacity in Zambia is low, which has both economical, and health implications 
for the health system. The current alternatives for diagnosis of malaria are clinical, 
microscopy and rapid diagnostic tests (RDTs). This study consists of an economic 
evaluation of the alternative malaria diagnosis methods in outpatient facilities in Zambia. 
The study is expected to contribute to effective decision-making in Zambia, especially 
when considering scaling up malaria diagnosis in health facilities. 
Methods 
A cost and cost effectiveness evaluation ofclinical, microscopy and rapid diagnostic test 
(RDT) diagnosis of malaria was conducted in 12 facilities in 4 districts in Zambia from 
the providers' perspective. Effectiveness was measured as cases correctly diagnosed by 
each strategy. Retrospective data (epidemiological and on costs) was collected from 
facility registers from March to November 2005. Principles of cost effectiveness analysis 
were applied to determine average and incremental cost effectiveness ratios of the 
alternatives, which were evaluated under routine conditions in health facilities. Based on 
the results, annual cost and effect extrapolations were made to estimate the potential 
impact of implementing the most cost effective method at district level. 
Results 
RDTs were found to be more cost effective (USD 6.5) than either microscopy (USD 
11.9) or clinical diagnosis (USD 17.1) for malaria. The incremental cost per case 
correctly diagnosed and treated was found to be USD 2.6 for RDT and USD 9.6 for 











assumptions and various parameters. The annual incremental cost of implementing RDTs 
at district level was estimated at usn 356,821. Cost savings on treatment were not 
significant in facilities with confirmatory strategies mainly due to prescription practices 
that include treating with antimalarials cases found negative. However, if the diagnostic 
strategy were to influence treatment decisions, savings on drugs of at least 56% could be 














The global burden of malaria today is estimated in terms of the epidemiological 
indicators and economic consequences. Malaria is a major public health problem in the 
world where at least 3.2 billion people are at risk of the disease annually (WHO 2000a). 
In its 2005 report, World Health Organisation (WHO) estimates that 60% of the cases 
and 80% of malaria related mortality occurs in Sub Sahara Africa (SSA) (WHO 2005). 
This shows that most malaria morbidity and mortality is being experienced utmost in an 
area geographically defined as the hub of poverty. Further, the true burden of the disease 
in SSA is expected to be sub-estimated as a result of under-reporting. For example it has 
been shown that as much as 70% of malaria cases in the region occur in the community . 
(Amexo et al 2004), thus such cases are not incorporated into facility figures and 
therefore not officially reported on. 
The consequence of such a huge burden of the disease has translated into economic losses 
by both individuals and health systems. When disability-adjusted life years (DALYs) are 
used to measure the burden of disease, WHO estimates that up to 45 million DALYs are 
lost due to malaria in Africa (WHO 2000a). In Africa alone, malaria would account for 
12 billion US Dollars loss due to health care related costs and a reduction in the 
production potential due to an episode of malaria (WHO 2005). It has also been reported 
that malaria slows economic growth. Malaria endemic countries show a reduction from 
0.25% to 1.3% in Gross National Product (GNP) per capita when compared to non­
malaria endemic countries (Sachs 2001, Greenwood et aI2005). 
Zambia has not been spared by the malaria burden. The disease is endemic countrywide 
and about 95% of all cases are caused by the mostly deadly species of the parasites 










Infol1l1ation System (HMIS) in 2004 showed that malaria accounts for 3 million clinical 
cases and 33,000 deaths annually. 
Uncomplicated cases of malaria could turn into severe malaria if cases are not promptly 
diagnosed and treated. Therefore, it is critical, in malaria case management, to be able to 
detect signs and symptoms of malaria early and thereafter treat with an effective 
antimalarial. It is for this reason that the Roll Back Malaria (RBM) emphasizes improved 
malaria case management as one of the pillars of reducing malaria disease burden (WHO 
2000b). 
It is against this background that in 2003, the national antimalarial drug policy in Zambia 
was revised. This led to the replacement of the failing chloroquine (CQ) and 
Sulphadoxine-pyrimethamine (SP) with artemisinin-based combination therapy (ACTs) 
for the treatment of uncomplicated malaria. Currently, ACTs have been scaled up 
countrywide to treat uncomplicated cases of malaria. ACTs have been reported to be 
highly efficacious in treating uncomplicated malaria and consequently reducing the 
transmission of resistant genes (Omari et al 2002, Chanda et al 2004, WHO 2005). It is 
therefore expected that by ensuring the efficacious drug is available countrywide, patients 
will receive effective treatment so as to avoid fatal outcomes. 
Nonetheless, malaria diagnostic capacity plays a pivotal role in correctly identifying 
malaria cases from non-malaria cases. This depends on the accuracy of a diagnostic test, 
which is detel1l1ined by its sensitivity and specificity. Sensitivity is defined as the ability 
of a test to correctly identify those with the disease, while specificity is the ability of a 
test to correctly identifY those without the disease of interest (Grimes and Schulz 2002). 
However apart from the test accuracy, other characteristics need to be considered, such as 
resources and time needed to perfol1l1 that test (Moody 2002). With an effective 
diagnostic tool for malaria, only true cases would be prescribed an antimalarial. This 
helps in channelling antimalarial drugs to those that need them and at the same time 











However, due to lack of diagnostic capacity to detect parasite presence in the patients, 
most fevers are being diagnosed clinically to be malaria. Consequently, antimalarial 
prescriptions are normally given to patients without any laboratory confirmation. 
Algorithms for fever management based on the integrated management of childhood 
illnesses (lMCI) guidelines are also being applied to ensure that other causes of fever are 
excluded (Gove 1997, Chandramohan et aI2002). Nonetheless, such IMCI guidelines are 
misapplied and only a few (33%) frontline health workers have actually been trained in 
IMCI (NMCC 2005). Further clinical algorithms have been unsuccessful in improving 
malaria diagnosis (Chandramohan 2002). This may be a contributing factor to poor 
patient management and has repercussions for the outcome of an event of malaria, 
especially in children aged five years and below in whom progression to severe malaria 
occurs rapid. 
The NMCC (2001) estimates show that in Zambia, only 34% of the facilities have 
laboratory facilities for microscopy services. Ofthese only 60% (about 20.4% of facilities 
countrywide) have functional laboratories. This is mainly due to the health system 
resource constraint to revamp the capital, human and other resource needs for this 
program. A recent survey, which was conducted in public health facilities in Zambia, 
with the aim of estimating the proportion of malaria cases being laboratory confirmed, 
showed that the proportion of malaria patients receiving treatment after laboratory 
confirmation was at 11 %. Furthermore it was shown that where laboratory diagnosis was 
introduced, there was a 31 % reduction in antimalarial use when compared to the times 
when there was no capacity to confirm malaria (NMCC 2005). This implies that relevant 
health personnel need to be equipped with the capacity to distinguish malaria cases from 
non-malaria cases through confirmatory tests such as microscopy or Rapid Diagnostic 
Tests (RDTs). 
There is a challenge now that Coartem® a fixed dose combination of Artemether­
lumefantrine (AL), which is being used to treat uncomplicated malaria, is more expensive 











estimated to be USD 2.4 for AL while that of CQ and SP is USD 0.10 to USD 0.20 
respectively (Yeung et al 2004). Due to the shift to a more expensive drug, the malaria 
drug budget in Zambia has increased from USD 579, 300.32 in 2003 (when SP was first 
line treatment) to USD 4,474,017.72 in 2005 (672.7% or 7.72 times). Without 
microscopy, it is difficult to exclude fevers, which are not due to malaria, thus the true 
burden of the disease proves difficult to quantify. This is leading to wastage of drugs on 
unnecessary treatment and one can also anticipate inappropriate patient management to 
be rampant Therefore, it is necessary to assess the economic implication of continuing to 
rely on clinical diagnosis as opposed to the introduction of a more accurate (and probably 
more expensive) diagnostic method in this era of ACTs. 
1.2 Rationale 
New technologies have introduced RDTs, which work on the principle of antigen 
detection methods. These immunochromatographic dipsticks can be sensitive to two 
basic antigens of the malaria parasites; the histidine-rich protein-2 (HRPII) or parasite 
lactate dehydrogenase (PLDH) (Hanscheid 2003). These tests are now being thought of 
as a viable option for defming malaria parasite presence in the patients suspected of 
having malaria. Compared to expanding microscopy services, RDTs can be easy to 
implement in the short term. This is because in order to have functional laboratory 
capacity, various inputs are needed such as trained laboratory personnel, a microscope, a 
building (where no structure already exists), reagents and other supplies such as slides 
and lancets (Moody 2002, WHO 2000c). RDTs however, can easily be used by any 
frontline health workers and do not need extra infrastructure (Guerin et al 2002). All that 
is required is someone who is able to draw a blood sample and read the test strips based 
on appearance of lines. (More details on RDTs are provided in Chapter 3, Section 3.3). 
There is a need therefore to come up with recommendations based on a systematic 
analysis of the diagnostic needs for malaria case management in Zambia. This study 
therefore seeks to compare the cost and cost-effectiveness of the three available options 












treatment. The cost implications of false positives (cases diagnosed as malaria in absence 
of the parasite) and false negatives (cases diagnosed as non-malaria in the presence of the 
parasite) will be determined. 
This study contributes to new knowledge on the economics aspects of malaria 
management. This is relevant since economic evaluations on malaria interventions, 
especially in Zambia, are scarce. Only two studies have been conducted so far in the 
Copperbelt province on integrated malaria control interventions and environmental 
management (Utzinger et al 200 I, Utzinger et al 2002). The results of this analysis will 
serve to inform policy makers on which alternatives will be most efficient in reducing 
malaria misdiagnosis by taking into account both the costs and effects of each strategy. 
Further options for research are also discussed. 
1.3.0 Aim and Obiectives 
1.3.1 Aim 
The aim of this research is two fold, firstly to assess the cost and cost-effectiveness of 
clinical, microscopy and RDTs techniques for diagnosing malaria in outpatient clinics in 
Zambia. This involved using primary data sources on costs and effects from 12 facilities 
in 4 study districts. The second aim is to use this data to estimate the net impact on costs 
(cost of technology minus the saving on treatment) and effects of scaling up cost­
effective malaria diagnosis up to district level. 
1.3.2 Specific Objectives 
1. 	 To determine the mean cost per patient with each diagnostic method in each 
facility. 
2. 	 To determine the monthly cost of false positives for each diagnostic method. 
3. 	 To determine the monthly cost of false negatives for each diagnostic method. 











5. 	 To determine the cost per correctly diagnosed case with each diagnostic method. 
6. 	 To analyse health workers prescription behaviour along with the diagnostic 
method used. 
7. 	 To determine the most cost effective of the three diagnostic methods along with 
incremental analysis between strategies. 












1.0 COUNTRY PROFILE - ZAMBIA 
2.1 Demographic and Economic Features 
According to World Bank estimates of world economies, Zambia is among the low 
developed countries in SSA. The country's population estimate for 2004 was 11.5 million 
inhabitants (http://siteresources.worldbank.org). 51% of the population are male and 49% 
female. Children under the age of five years account for about 17.5% of the population. 
The majority of the population lives in rural areas (65%). The annual popUlation growth 
rate is estimated to be 2.9% and the average household size is 5.4. The crude birth rate is 
41.46 births per 1,000. The national literacy rate is estimated at 63% for males and 50% 
for females Zambia Demographic Health Survey (ZDHS) 200112002). The life 
expectancy is at 47.5 years for males and 51.7 for females, and the total fertility rate is at 
5.9 (ZDHS 200112002). 
The climate in Zambia is typical of the sub tropics region. The three main seasons are 
defmed as cool dry winter (May to August), hot dry season (September and October), and 
warm wet season (November to April) (ZDHS 2001/2002). 
Administratively, the country is divided into nine provinces namely Lusaka, North 
Western, Northern, Luapula, Eastern, Western, Central, Southern and Copperbelt. Of 
these provinces, only Lusaka and Copperbelt are considered to be urban and form the 
main hub of economic activity in Zambia (ZDHS 200112002). The provinces are further 
divided into a total of 72 districts countrywide. 
The economic activity has since the early nineteenth century been centred on the mining 
industry with copper as the main output. Other industries include manufacturing, 











reported a positive real economic growth rate of 4.6% in 2004. This meant that there was 
a consequent increase in funding to social sectors such as health. Nevertheless, the high 
inflation rate (17%) continues to have a negative impact on the real value of health sector 
funding by government (MFNP 2004). 
The reported increase in Gross Domestic Product (GDP) is also negated by an increase in 
population making real GDP growth almost non-existent. In 2002, GDP per capita was 
estimated at 865 international dollarsl. The National Health Accounts (NHA) analyses 
have also shown that general government expenditure on health (GEH) has remained 
almost stagnant from 1998 to 2002 at just around 52% (WHOSIS, 
http://www.who.intJnhalcountry/en). Expenditure on health as a proportion of gross 
domestic product (GDP) is only 5.8%1. 
Unemployment continues to be high generally due to the negative effects of the economic 
reforms. This was during the privatisation process of formerly government owned 
parastatals, which began in 2001 (NHSP 2005). It is not surprising then that even in the 
health sector, a human resource crisis is looming. A Human Resource Development 
Review in 2004 showed that about 50% of the required core health worker positions (at 
all levels of health care) were still vacant (MOH 2001). This has made it difficult to 
manage the growing needs for patient care mainly due to malaria, HIV IAIDS and 
Tuberculosis (TB) to mention but a few. 
It is estimated that about 70% of the population lives on less than USD1 per day, which 
the World Bank has defIned as the poverty line. Income is inequitably distributed (Gini 
coefficient = 0.57i with the rural areas being more equitable (0.42) than the urban areas 
(0.61) (CSOILCMS 2002-2003). There are noticeable differences in health status 
between the rural and urban areas. This is also partly due to the fact that poverty levels 
I WHOSIS, available at http://www.who.intinha/countrylZMB.xls, accessed 51b October 2005. 
2 Gini coefficient measures the income inequality in a population and ranges on a scale of 0 (0 1. With I 











are worse off in the rural areas (80%) as compared to urban areas (50%) (MOH 2003). 
Inequities in health service delivery exist among rural and urban areas. For example, the 
doctor to patient ratio was 1 :5000 in Lusaka Province (urban) whereas it was 1 :43000 in 
rural Luapula Province in 2004 (MOH 2004). 
2.2 The Health System Context 
2.2.1 Health System Structure 
The health system decentralization policy was implemented in Zambia since 1998. What 
this meant was that the MOH, the umbrella body for all health activities was responsible 
for the legislature, setting policy direction and fmancing of the health system. Whereas 
the Central Board of Health (CBOH), a technical body ratified by parliament to 
implement government health programmes, has been delegated to manage the district 
action plans of the health sector. This led to the formation of 72-district health 
management boards (DHMBs), which were responsible for implementing health 
programmes (Bossert et al 2003). This purchaser-provider split was seen as a way of 
ensuring that the policy and operations roles are carried out more effectively. The 
jurisdiction of the DHMBs includes District Hospitals, health centres, health personnel 
training institutions and the community level neighbourhood health committees (NHCs) 
which is the lowest entry point into the structure of health service (Bossert et al 2003). 
The community level is defmed as a level that 
"brings health care as close to the family as possible. Community health workers (CHWs) 
are expected to promote preventive measures, proVide individual counseling and group 
education, detect cases offever and pregnancy, provide simple case management and 
prophylaxis, and know when to refer". (NHSP 2005). Due to human resource shortages, 
CHWs sometimes have ended up operating at health centres (especially in rural areas). 
However, attempts are being made now to devolve functions to local authorities in the 
district councils (political administrators), which wo?ld in turn manage the districts 












provincial office and central level. However, decision-making may revert to a system 
similar to a centralized health system. By March 2006, an Act of Parliament was repealed 
allowing the dissolution of CBOH. Even so, there is no further information as to what the 
next steps will be and the DHMTs have continued to operate as per decentralized 
structure. 
2.2.2 Health Care Provision and Financing 
The overall goal of the health system in Zambia is "to provide Zambians with equity of 
access to cost-effective, quality health care as close to the family as possible. " (MOH­
NHSP 2005). In line with this goal, the basic health care package is provided through 
public service based on the priority disease burden. User fees are charged to patients at 
the point of seeking care. An exemption policy however, exists for the treatment of 
chronic illnesses, sexually transmitted diseases, family planning services, treatment of 
epidemics, children under five and adults older than 65 years of age (CBOH 1998). 
However effective implementation of user fees policy has proved difficult due to the 
extent of poverty. Most people are unable to pay and only a few urban-based facilities 
have managed to raise some income (Bossert et al 2003). Plans are now under way to 
remove the user fee policy in lower level health facilities. 
There are about 1,327 health facilities, 1,124 are government owned, 115 are private 
sector clinics and 88 are mission facilities (CBOH 2002). The major causes of illness in 
these facilities include, malaria (which is endemic countrywide), respiratory infections, 
diarrhoea, pneumonia and trauma. Other common diseases include HIV/AIDS, TB, 
urinary tract infections, sexually transmitted diseases and non-communicable diseases 
(MOH NHSP 2005). The maternal mortality rate is among the highest in the world (729 
per 100,000 live births), whereas under five mortality rates is at 163 per thousand 
population (MOH NHSP 2005). Table 2.1 illustrates some of the key health indicators. 
The estimates for SSA have also been incorporated to allow for comparative 











a e . ey ea lca ors orT bl 21 K H lth Ind' t f, Zamb'la an dSubSaharan Afr' lca 
Indicator Zambia 2003 SSA Average 
2004** 
Life expectancy (Years) 43 46.2 
Infant Mortality Rate (per 1000 live births) 95 100.5 
Maternal Mortality Rate (per 1000 live births) 729 870 
Child Mortality Rate (per 1000 live births) 168 168.2 
Low Birth Weight (for every 25 births at facility) 1 .. 
Fully Vaccinated Children (FVC) (%) 74 64.5 
HIV Prevalence (% among those suspected) 15.6 .. 
Malaria Prevalence (HMIS 2003)* 428/1009 .. 
Sources: ZambIa Health and DemographIc Survey (200112), Annual Health StatistIcs 
Bulletin (2003), *HMIS estimates (including both confIrmed and unconfIrmed cases), 
**World Bank 
2.3.0 Malaria Situation Analysis in Zambia 
2.3.1. Malaria Burden 
According to the ZDHS, malaria is the leading cause of mortality and morbidity, 
accounting for 37% of all out patient attendances at health facilities (ZDHS 2002, MOH 
2004). Current trends show at least 3 million clinical cases and 33,000 deaths are reported 
annually from all public health facilities. It is anticipated that these cases could be more if 
unreported cases of disease and community deaths are included. By 2004, the CBOH 
reported a prevalence of 428 cases per thousand populations countrywide. Furthermore, 
malaria is responsible for 40% of the under fIve deaths and 20% of maternal mortality 
(CBOH 2004). The incidence of malaria has been fluctuating over the past years. 
However, the general trend is an increase in cases from about 120 per thousand 
population in 1976 to more than 300 cases per thousand population in 2004 as shown in 
fIgure 2.1 below. Note that the period 1994 to 1998 shows a data gap due to the structural 
changes in the reporting system from the previous health services information systems to 
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Figure. 2.1 Reported Number ofMalaria Cases per Thousand 
(Incidence) 
Year 
Source: National Malaria Control Strategic Plan, 2006 (NMCC 2005). The number of malaria cases 
includes both confmned and unconfirmed cases at the facility level. 
The vector species, which are responsible for the transmission of malaria, are the 
Anopheles gambiae, Anopheles arabiensis and Anopheles funestus complex (NMCC 
2000). These are known to be very efficient in transmission of the malaria parasites. 
Plasmodiumfalciparum is the most prevalent in Zambia accounting for about 95-98% of 
the malaria cases, whereas P. malariae and P. ovale have been reported in about 5% of 
the cases countrywide. Plasmodium vivax is said not to be a causal agent for malaria in 
Zambia (NMCC Situation Analysis 2000). The prevalence of the most deadly form of the 
malaria parasite and the most efficient vectors coupled with a warm climate has made 
malaria control in Zambia a big challenge. 
As early as 1944, the then Rhodesian government instituted the Mosquito Extermination 
Act to control malaria in the then Northern Rhodesia. The primary requisite of this Act 
was to warn the cornmunities of any accumulation of water in their surroundings 











in form of a fme instituted by the city council (NMCC 2000). This not only prevented 
malaria but also other water borne diseases. The copper mining industry, early in the 
1950s, had also invested significantly in malaria control in the urban areas, given the 
good economic performance at that time (Utzinger et aI2002). The rural areas were using 
19thchemoprophylaxis for malaria prevention in school children. Thus, in the mid 
century, malaria became a notifiable disease in the Copperbelt and the City of Lusaka, 
while the rest of the country had very low prevalence of malaria (NMCC 2000). 
The decline in copper prices in the late 1970s and the Stockholm Convention ban on the 
use of DDT for malaria control in 1972 brought about the beginning of increase in 
malaria incidence from 137 per thousand populations in 1976 (NMCC 2000) to 428 cases 
per thousand populations in 2003 (CBOH 2003). The increase in incidences has 
consequently increased expenditure on malaria and this has created a resource burden on 
the under funded health system (NMCC 2000). 
CQ and SP were the main drugs used to treat malaria. However, the recent times have 
seen an increase in multi drug resistance to commonly used antimalarials. Sentinel site 
surveillance of the therapeutic efficacy of antimalarials have been conducted in country 
based on the recommended WHO protocol (WHO 2003). These have shown that 
treatment failure to CQ is greater than 50% while that of SP show as high as 32% in 
certain parts of the country (Barat et al 1998, Chanda et a12004a, Chanda et aI2004b). 
The consequences of drug resistance have been reported to be prolonged illnesses, 
increased morbidity and mortality, thus negating malaria control efforts being made by 
countries (phillips & Phillips-Howard 1996). 
As a result of the myriad of factors mentioned above, malaria control is now high on the 
nation's health agenda. The following section discusses the various malaria control 
interventions which are being implemented in order to effectively reduce malaria related 











2.3.2 Malaria Control Efforts 
In April 2000, the Abuja Declaration for REM was instituted and, malaria endemic 
countries reaffirmed their commitment to prioritise malaria control so as to halve the 
disease burden by 2010 (WHO 2000a). Zambia as country is a signatory to the Abuja 
Declaration and thus ascribes to its ideals and goals. To this effect, the National Malaria 
Control Programme (NMCP) in Zambia has embarked on a strategic process of 
implementing the REM objectives. The interventions, which have been adopted by the 
NMCP, include vector control, improved case management, behaviour change 
communication, partnership strengthening and, monitoring and evaluation, including 
research. 
2.3.2.1 Improved Case Management 
Under this component, efforts are being made to ensure early detection and treatment of 
malaria. Due to increase in parasite resistance to CQ and SP, the antimalarial drug policy 
has been revised. AL has been declared a first line treatment for uncomplicated malaria 
except for children under 10 kg and pregnant women, in whom SP is being used. By 
December 2004, AL was available in all public facilities in the 72 districts (Mudondo et 
al 2005, NHSP 2005). Quinine is still being used as second line treatment. For malaria in 
pregnancy, Quinine is being used in the first trimester ofpregnancy, SP in the second and 
third trimester for treatment and also for intermittent presumptive treatment (IPT). 
2.3.2.2 Integrated Vector Management 
Indoor residual spraying (IRS) is carried out in selected districts in Zambia based on level 
of urbanisation and malaria incidences. The insecticides being used are pyrethroids and 
DDT. Currently 15 districts are implementing this intervention under the auspices of 
malaria control programme in collaboration with various partners. The partners involved 
in the spraying operation include the private sector, bilateral and multilateral 











protected at an average direct cost of USD 1.41 per person and USD6.55 per household 
protected in the 2004 season (NMCC 2004a). 
The Insecticide Treated Nets (ITNs) programme in Zambia is another strategy being used 
for personal protection against mosquitoes. Taxes and tariffs on mosquito nets and 
insecticide for re-treatment have been removed (NMCC 2004b). The delivery 
mechanisms use different approaches to reach various target groups based on disease 
burden and also on socio-economic status. According to ZDHS, 27.2% of households 
surveyed owned at least a bed net. However, those who owned ITNs were 17.7% (ZDHS 
2001/2002). It is expected that by now, these rates have improved given the scaling up 
efforts. The school health programme is another initiative in which ITNs are being 
provided to all boarding schools countrywide in a bid to revamp malaria control efforts in 
schools. Re-treatment campaigns for all ITNs in the community ar  intensified during 
Child Health Week activities. 
2.3.2.3 Information. Education and Communication 
Information dissemination is key for malaria control. The Information, Education and 
Communication (1EC) department at NMCC works with various partners in order to 
provide useful information to different audiences on malaria control aspects in Zambia. A 
communication strategy has been developed with collaboration from bilateral and 
multilateral partners. This is to ensure that information is disseminated in a systematic 
way. Communication channels being used include television, radio, leaflets, pamphlets 
and drama. Translation of information guides into the main local languages is also done. 
2.3.2.4 Monitoring, Evaluation and Research 
The NMCC has developed a strong emphasis on monitoring the progress and impact of 
malaria control interventions. This helps to provide the necessary and timely information 
to suit the programme needs and serve as evidence base for policy decisions and 












based on NMCC recommendation. The group coordinated by NMCC is composed of 
partners from universities (local and foreign), research institutions, private sector and 
NGOs. Quarterly meetings help to disseminate research areas among institutions and also 
to report on programmes monitoring progress. Various studies have been conducted on 
antimalarial drug use (efficacy and compliance), knowledge, attitudes and practices of 
malaria (KAP studies), insecticide resistance monitoring, and IRS monitoring and other 
areas. Draft guidelines for malaria research in the districts have been produced to 
demystify research and encourage district level staff to engage in applied research. 
Close collaboration of the surveillance office with HMIS and Central Statistics Office 
(eSO) and other regions helps to integrate efforts in information collection, analysis and 
presentation. Epidemic preparedness is also another key area because some areas in 
Zambia are prone to epidemics especially those near major rivers and lakes where floods 
occur frequently. 
2.3.2.5 Resources for Malaria Control 
Financing of malaria control in Zambia is made possible by support from government 
and partners. About 32% of the malaria expenditure is government funded while various 
donors fund the larger proportion. These include multilateral, bilateral, the private sector 
and other local partnerships. Broadening the partnership base is key to ensure that the 












2.0 LITERATURE REVIEW 
3.1 Theoretical Background ofMalaria Diagnosis 
Malaria is transmitted through a mo.squito. bite by an infected female Anopheles sp 
mo.squito.. When the parasites have been injected in the bo.dy, they multiply in the liver 
and then get released in the blo.o.d stream leading to. a myriad o.f sympto.ms. These 
sympto.ms include o.ne Qr mo.re o.f the co.nditio.ns as sho.wn in Table 1 (first cQlumn). At 
this stage malaria is co.nsidered to. be uncQmplicated Dr simple. 















Severe anaemia due to. haemo.lysis 
Haemo.glo.birunia 
Acute respiratory distress 
CardiQvascular co.llapse and sho.ck, etc 
Adapted from Zambia Malaria Foundation website: http://www.malaria.org.zm/treatment.hml 
Severe (Qr co.mplicated) malaria on the o.ther hand, o.ccurs when the initial unco.mplicated 
malaria is either no.t reso.lved (due to. treatment failure) Qr no.t detected early. Late 
detectio.n o.f malaria CQuld be due to. patient health care access pro.blems, the stage at 
which the detectio.n is perfo.rmed, the type o.f test being used and or health wo.rker 
perfo.rmance capacities o.n diagno.sis. So.me o.f the co.mplicatio.ns o.f severe malaria are 











It has been said that the failure to effectively control malaria is in part due to "inability to 
deliver appropriate case-management to a significant proportion ofpatients, particularly 
at the periphery ofhealth systems" (Guerin et al 2002). This observation is true because 
in order for a case of malaria to be detected, the diagnostic method must be appropriate 
(sensitive to the parasites in question). Furthermore, for the identified case of malaria to 
be successfully treated, the treatment given to the patient must be appropriate (have 
sufficient efficacy to clear parasites from the blood). Additionally, being able to correctly 
identify those with the disease will not only cure them, but is said to help reduce malaria 
transmission by clearing parasite reservoirs of the infected person (Mendiratta et al 
2006). In this way malaria diagnosis serves both as a curative and preventive strategy. 
WHO, in its "New Perspectives for Malaria Diagnosis" (2000c, page 5) paper emphasises 
the need for "prompt and accurate diagnosis" of malaria as a prerequisite to successfully 
care for malaria patients. It is therefore important that health workers and the caretakers 
of patients are aware of this important fact. However, the objective of ''prompt and 
accurate diagnosis" of malaria (WHO 2000c, page 5) is affected by other health system 
factors. For example good access to health care services provided by trained personnel is 
limited and where these exist, specifically laboratory services may be unavailable (Guerin 
et al 2002). At this stage, it is possible to see why malaria diagnosis is usually described 
to be a challenging issue by several authors (Moody 2002, WHO 2000c, Hanscheid 
2003). 
Moody (2002), in his review of malaria diagnosis points out that the main challenges of 
malaria diagnosis include: Morphological variations in the parasite itself at the different 
stages of its life cycle, these changes also vary with the emergence of drug resistance, the 
parasites diversity and complexity of blood collection techniques. These issues are key in 











Different methods of diagnosing malaria have been outlined in literature. Currently, 
various approaches have been defmed by WHO (2000c). These include clinical 
diagnosis, light microscopy, fluorescent microscopy, antigen detection (RDT), 
polymerase chain reaction (PCR) and haemozoin-containing leukocytes-automated full 
blood count analyser. These methods differ in technique, capacity and effectiveness. Of 
these alternatives, PCR, fluorescent microscopy and full blood count analysers are not 
used in routine conditions. The choice of which strategy to implement depends on several 
factors as outlined in Table 3.2 below. 
Table 3.2 Factors Affecting Choice ofa Diagnostic Method 
• The extent of malaria endemicity 
• The prevalence of drug resistance 
• Geographical access to health services 
• Socio economic situation 
• The level of infrastructure in the health system under consideration 
• The availability of diagnostic tools 
Source: Adapted from WHO 2000c. 
The following review will concentrate on the three strategies, which are commonly used 
in Zambia and are the subject of this study. 
3.2 Clinical Diagnosis ofMalaria 
Clinical diagnosis of malaria is a strategy of malaria diagnosis based on signs and 
symptoms of malaria (WHO 2000c). The commonly used symptoms include a history of 
fever, increased breathing rate, anaemia, convulsions, inability to feed, to mention but a 











developed by WHO to improve clinical detection of childhood illnesses. IMCI guidelines 
recommend that children with fever or history of fever and or pallor qualify for 
antimalarial treatment (Tarimo et al 200 I). Other predictions ofmalaria have included the 
use of fever with a previous history of malaria coupled with absence of cough, presence 
ofenlarged spleens (commonly referred to as splenomegally) or pallor (Muhe et al 1999). 
An extensive prospective evaluation conducted by Luxemburger et al (1998) in Thailand 
also identified other combinations for predicting malaria infection. These included fever, 
nausea, clinical anemia, palpable spleen, palpable liver, headache and, absence of cough 
and diarrhoea. Among these factors, the study showed that vomiting, confirmed fever, 
splenomegally and hepatomegally were by themselves risk factors for Plasmodium 
Jalciparum malaria. They however concluded that these methods were unsuccessful in 
accurately detecting malaria infections. 
Evidence from Malawi (Redd et al 1996) demonstrated that even though all children with 
fever were supposed to be treated as malaria, there was a need to include splenomegally 
and pallor. This would make the diagnosis even more effective. It was thought that by 
better derming malaria cases, the concerns ofover-treatment would be averted. 
Despite all the possible determinants of clinical diagnosis for malaria discussed above, 
the most widely used is fever greater or equal to 37.5 degrees Celsius (febrile), or history 
of fever and pallor. The presence of these symptoms may indicate uncomplicated malaria. 
On the other hand, convulsions or history of convulsions, unconsciousness and severe 
anaemia are good indicators of severe malaria (WHO 2004, NMCC 2004c). 
In Africa, it has been reported that fever is often the main feature of clinical diagnosis of 
malaria (WHO 2000c). This is so, mostly because access to health facilities is still a 
problem in many countries on the continent. Furthermore, according to Amexo et al 
(2004) most cases may occur in the community. These patients lack access to trained 
medical personnel. Yet, even where medical personnel exist, laboratory services in these 











In order to try and improve the effectiveness of clinical diagnosis, approaches are being 
made to pre-test various algorithms. The main aim is to improve the specificity (i.e. 
reducing false positives) of clinical malaria diagnosis. In order to achieve this, various 
researchers have tried to combine one or more of the other signs and symptoms of 
malaria with the widely used fever. 
A study was conducted by Mwangi et aI, (2005) in Kenya to assess the effectiveness of 
clinical algorithms in diagnosing malaria in different age groups. The study took place in 
Kilifi (an area of moderate malaria transmission) with 1602 participants reporting fever 
or history of fever in an out patient clinic. Clinical diagnosis was compared with 
microscopy confirmation of malaria. The main conclusions were that when age specific 
algorithms were used as basis for treatment, 16% of those aged five years and below, 
44% of those aged 6-14 years and 66% adults eligible for antimalarial treatment would 
not receive any treatment. This was despite these cases having a history of fever and 
parasitaemia. This study demonstrated that in an effort to improve specificity, false 
negatives were increased. Thus there was a concern that clinical diagnosis using 
algorithms may not be useful in targeting treatment to the most vulnerable groups and 
may increase prolonged malaria morbidity. 
In Pakistan, a study was conducted in low malaria endemic area among patients aged 6­
12 months in a rural health centre (Hozhabri et al 2002). Different combinations of signs 
and symptoms were assessed and compared with microscopy at predicting Plasmodium 
Jalciparum malaria. Fever in the past thre.e days or more and absence of cough or rigours 
was found to have a sensitivity of 100% and 63% specificity. However, WHO 
recommends that malaria detection be conducted within 24 hours of onset of symptoms. 
So, if the more than 3 days history of fever was adopted, a lot of cases could be missed 
from being detected and this would consequently increase incidence of severe malaria, 












Chandramohan and colleagues (2002) conducted a review of several studies that used 
clinical algorithms to diagnose malaria. They assessed different epidemiological zones to 
establish the risks and benefits of the algorithms. They concluded that in low endemic 
settings, the risk of false negatives was low. They also reported that the savings on over 
treatment was not significant in low malaria transmission areas. However, in endemic 
areas,. the false negatives increased with an increase in prevalence. They concluded that 
clinical algorithms were inaccurate and could not be used as a basis for treatment. This 
was also found in India where different combinations of clinical symptoms were used to 
get the highest possible score based on ability to predict malaria correctly in adults and 
children (Chandramohan et al 2001). The highest scoring algorithms had 60% sensitivity. 
They further said that the IMCI recommendation of treating all febrile cases (or history of 
fever) was better than other clinical algorithms if microscopy confirmation could not be 
within reach. It was concluded that clinical diagnosis was poor in predicting malaria. It 
was also suggested that microscopy confirmation is needed so as to improve the accuracy 
of malaria diagnosis. 
Other studies have used various signs/symptoms and differences in endemicities. In low 
malaria transmission Luxemburger et al (1998) evaluated several signs and symptoms of 
malaria to assess their association with a true ma~aria diagnosis in Thailand. 1527 
children were prospectively followed up and 9 signs and symptoms were evaluated. 
Using history of fever, headache and absence of cough was 51 % sensitive and 72% 
specific. History of fever and oral temperature greater or equal to 38 degrees Celsius gave 
a 51% sensitivity and 71% specificity. However when using fever greater or equal 37.5 
degrees Celsius in a low transmission area in Zambia clinical diagnosis of malaria when 
compared with microscopy was found to be 70.6% sensitive and 35.6% specific. 
Conversely, in a high transmission area, it was 93.3% sensitive and 25.5% specific 
(Ndhlovu et al 2004. MOH Report unpublished). These studies show that clinical 
diagnosis produces different accuracy depending on the definition used and the 












Other studies have compared clinical diagnosis with either RDTs or microscopy. In 
Tanzania, a study was conducted to compare the IMCI strategy (treating all fever and or 
pallor cases) with RDTs (validated by microscopy) in a low endemic area (Tarimo et al 
2001).395 children who were identified to receive antimalarial treatment using the IMCI 
strategy were tested for malaria parasites using microscopy and RDTs. 70% of these 
actually had malaria parasites (30% false positive). Fever was found to have a sensitivity 
of 93% and 15.5% specificity. However, pallor had a sensitivity of 72.2% and 50.8% 
specificity. The ICT brand ofRDTs were found to be 100% sensitive and 74% specific, 
while the OptiMal brand was 100% sensitive and 100% specific (Please see RDTs 
section 3.3 for more details on the differences between these brands). The study 
concluded that financial limitations might inhibit the use of RDTs for routine malaria 
diagnosis if the antimalarial drug is cheap. But if the drug of choice is expensive, the 
opposite may be true. 
In Ethiopia, Muhe et al (1999) assessed the improvement of malaria prediction by 
including pallor and splenomegally to fever or history of fever. Microscopy was used as a 
gold standard. The study included a total of 2490 children between 2-59 months in low 
and high transmission seasons. It was found that pallor and splenomegally improved 
malaria prediction capacity both in the low and high transmission seasons. Fever and 
pallor reported sensitivity and specificity of 83% and 75% respectively in the high 
transmission season. During the low transmission season, the effectiveness of diagnosis 
reduced showing a sensitivity of 51 % and 60% specificity. However, fever and 
splenomegally were 80% sensitive and 69% specific in the high transmission season. But 
during the low transmission season, fever and splenomegally were 65% sensitive and 
81 % specific. 
One of the earliest evaluations of IMCI was conducted in Kenya during a high malaria 
transmission season (Perkins et al 1997). 1795 children aged 2months to 5 years were 
enrolled over a 7 months period. 67% had microscopically confirmed malaria and 80% 
had anaemia (haemoglobin <11g/dl). The assessor was a health worker trained in IMCI 












found to be 100% sensitive and 0% specific. Based on these, recommendations were 
made to revise the IMCI strategy. Malaria was found to have symptoms and signs similar 
to pneumonia and malnutrition. This shows implementing IMCI still results in poor 
malaria prediction even by trained personnel. Thus, health workers who are not even 
trained in IMCI should be expected to perform even worse. 
3.3 Microscopv Diagnosis ofMalaria 
Malaria diagnosis using microscopy (light microscopy to be specific), under ideal 
conditions is up to date considered to be the gold standard (Guerin et al 2002, Hanscheid 
2003). Unlike clinical diagnosis of malaria where only one clinician is involved, this 
strategy needs a minimum of two personnel: a clinician and a laboratory technician. The 
initial stage involves a clinical diagnosis of the patient by a clinician. The clinical 
diagnosis is performed based on the signs and symptoms that a patient may present with 
(as discussed in Chapter One - section 1.1 above) at the facility. If a clinician suspects 
malaria, the patient is sent to the laboratory to obtain a confirmation of malaria infection. 
Once laboratory investigation for malaria is complete, armed with a laboratory result, a 
clinician may decide to treat or not treat. 
In order for the laboratory personnel to be able to detect malaria parasites, there are basic 
steps that are supposed to be accurately followed. Initially, blood is collected by way of a 
finger prick or otherwise using a sterile lancet. The drop of blood is then smeared on 
glass slide manufactured for this purpose, then the slide is dried by either a heater of 
blower. After that, the slide is stained in a standard dilution of Giemsa stain for up to 15 
minutes (for a quick count) or 30 minutes (for a slow count). Quick counts usually serve 
the purpose of identification ofparasite presence and are used in routine clinical practice, 
where as slow counts are used in monitoring therapeutic efficacy and help to make better 
estimations of parasite counts. After staining, the slide is then read under oil immersion 
using a conventional light microscope. Details of this procedure have been described in 











(1998), it was said that malaria endemic countries expenditure on health are too low to 
allow for extensive investments in malaria microscopy. This has led to a situation where 
only a few facilities in main referral centres and hospitals are actually able to provide the 
service. It has been observed that most of microscopy services are not widely available in 
most areas where they are needed especially in the SSA region (Guerin et al 2002, 
Moody 2002). 
Furthermore, where services are available, the possibility of attaining high sensitivity 
levels under routine conditions is questionable. This is because in a typical clinic setting, 
a lot of people may be waiting for results. Thus a laboratory person may be likely to rush 
through the tedious procedures. Human resource constraints may also lead to heavy 
workloads and thus concentration is disturbed. Under these conditions, it is likely that the 
quality oflaboratory results may be compromised (Guerin et al 2002). 
WHO estimates also show that sensitivity of microscopy diagnosis of malaria under 
routine conditions may be 10% less than the expected sensitivity of expert microscopy 
(WHO 2000c). Other studies have also reported that only up to 90% of all routine 
microscopy diagnoses were correct (Milne at al1994 in Hanscheid et aI2003). 
Another issue of concern is that laboratory procedures take a longer time to perform, 
thereby contributing to long waiting hours. The minimum time it takes to get results may 
be 30 minutes and more. Due to this, it has been reported that clinicians are more likely 
to treat without laboratory results. Hence, the investigation ends with no role in the 
decision making process of the clinician (Moody 2002). Therefore, the extra cost of 
conducting laboratory investigations (for unutilised results) and the opportunity costs for 
the microscopists are a drain on the limited resources of the health system. Amexo et al 
(2004) have pointed out that misdiagnosis of malaria have negative consequences on the 
illness outcomes and poverty. 
In the case of highly endemic countries, it has been reported that members of a 












In these cases, a malaria positive laboratory result may not be predictive of the actual 
reason for visit to the health centre. This also may be an ingredient for patient 
mismanagement. 
Moody (2002) has further outlined other threats to the validity of microscopic results. 
These include the observation of a negative slide when in the actual fact; parasites are 
sequestered in body tissues and not circulating in peripheral blood. This may lead to false 
negatives and thus misdiagnosis of malaria. Lastly, dead parasites may be observed (post 
treatment) and this may be misinterpreted as treatment failure. It is for this reason that 
laboratory personnel need to have a better understanding of the various dynamics of 
malaria (Hanscheid et al 2003). 
Various studies have been conducted in which microscopy has been recommended to be 
the better method for malaria diagnosis and disease estimation. In Malawi, microscopy 
confirmation of malaria was estimated to lead to about USDI4, 000.00 savings on annual 
drug costs when compared to presumptive treatment during the rainy season (Jonkman et 
al 1995). Such savings could help in reprogramming of resources to other areas of need. 
Additionally, field evaluations in several countries have shown that microscopy was able 
to detect fewer cases than those detected by clinical investigation only. In Tanzania, 
when IMCI diagnosis was compared with microscopy and RDTs in an endemic situation, 
only 70% of those treated presumptively were found positive by microscopy (30% false 
positives according to microscopy) (Tarimo et al 2001). In a study by Guthman et al 
(2002), in Uganda, in an out- patient setting, only 57% of those who were clinically 
suspected of having malaria were positive with microscopy. Another study conducted in 
Thailand by Stephens et al (1999), showed that clinical diagnosis overestimated the 
malaria burden. Only 32% of the cases clinically diagnosed as having malaria were 
positive with microscopy. 
In Zambia, a study was conducted by random selection of health centres during high 












diagnosed malaria cases, only 74/335 (22.09%) actually had malaria parasites detected by 
expert microscopy methods. Hence 49.25% (165) would have been false positives 
(Ndhlovu et al 2004). Thus, diagnosis of malaria using microscopy has a major role to 
play in correctly identifying mono-infections from mixed infections and that if correctly 
interpreted and utilised, microscopy can assure treatment within 30 minutes and avoid 
secondary illness ( Penine et al 1998). 
However, the true sensitivity and specificity of microscopy under routine conditions has 
not been well documented. Colin et al (2002) have argued that since most of the times 
microscopy is the reference method, its poor performance in routine settings is difficult to 
estimate. In the same paper, the authors demonstrated that in trial settings, basic 
microscopy (routine) was found to be 91% sensitive and 71% specific when compared 
with expert microscopy. 
3.4 Rapid Diagnostic Test Malaria Diagnosis 
RDTs are immunochromatic dipsticks used to diagnose malaria. They are a relatively 
new technology in malaria, which uses "non-microscopic methods", and as the name 
suggests they are rapid. It is possible to get results within 5-15 minutes, depending on the 
type ofRDTs (WHO 2000c, Guerin et aI2002). 
The RDTs detection methods are based on immunology, where the monoclonal 
antibodies are fixed on the test strip (or dip stick immunochromatographic paper) during 
the manufacturing process. When these come into contact with infected blood, they bind 
to specific antigens produced by malaria parasites. The main antigens, which have been 
used, include HRP-2 and pLDH (Guerin et al 2002). The HRP-2 antigen is common on 
the membranes of Plasmodium falciparum especially in the asexual and young 
gametocytes. Unlike HRP-2, the pLDH protein can detect isomers for each of the four 
types of parasites that exist (Moody 2002). Hence pLDH can be used to detect any of the 












infections from those caused by the other three species (P. malariae, ovale and vivax) 
(WHO 2000c). 
The steps involved in performing RDT malaria diagnosis have been outlined elsewhere 
(WHO 2000c) and are summarised in the following account. Like in microscopy, the 
finger prick is the starting point so as to generate a blood sample. The blood sample is 
then mixed with a buffer solution in a capillary tube (or test wells). The buffer contains 
agents, which are able to haemolyse, the red blood cells so as to release the contents of 
these cells. Once haemolysis is complete, the antibodies on the capillary binds to the 
parasite antigens present in the blood so as to form antigen-antibody complex. This 
complex then moves along the test strip migrates by capillary action and after some time, 
the control line appears on the test strip. Then, if parasites are present, a second line (test 
line) appears thereafter. Moodyet al (2002), provide more detail on the scientific basis 
for each of these steps. 
WHO acknowledges that RDTs are increasingly gaining attention for their practical use 
given the limitations of scaling up microscopy services (WHO 2000c). These sentiments 
have been observed by other researchers working in malaria due to the various 
advantages RDTs have over microscopy. 
RDT diagnosis of malaria has been said to be rapid and requiring less inputs than 
microscopy (Guerin et al 2002). In the case of microscopy, at least a clinician and trained 
laboratory personnel is required whereas the RDT method only needs a clinician or a 
nurse. This is an opportunity for health systems where staff shortage is raging. 
Additionally, it has been reported that no specialised personnel are required to perform 
this test (Moody 2002, Guerin et al 2002). Moody (2002) has expressed that RDTs have 
the potential to move diagnosis services from central level laboratories to areas where 
patients need them. 
The applicability of RDTs in areas or situations where malaria microscopy is not feasible 












(WHO 2003), mobile clinics and in rural areas where electricity supplies may be non­
existent (Guerin et al 2002). Other situations in which RDTs would be more applicable 
than microscopy have been reported to be in travellers, military forces and organised 
workforces in malarious countries (WHO 2000c). These situations have demonstrated 
that RDTs are more practical than microscopy. 
Since RDTs are relatively easier to use and take less time to produce results (to-15 
minutes) (WHO 2000bc), they have the potential to reduce the long waiting time at health 
facilities. This will go a long way in improving malaria case management especially in 
rural areas where microscopy services may not be readily accessed. 
However, the perception that RDTs are simple to use should be interpreted with care. 
Hanscheid (2003) stated that health workers should at least be aware of various dynamics 
involved in malaria transmission. This is so because a failure to get a test line may not 
necessarily mean the patient does not have malaria. 
Disadvantages of RDTs have been widely debated thereby presenting policy makers with 
the main issues to consider when deciding among diagnosis strategies. WHO estimates 
have shown that the cost per unit of RDT ranges from USDO.60 to USD2.50 (WHO 
2000c). Other estimates have reported the unit cost per RDT to be USD 0.50 to USD 3.00 
(Guerin et al 2002). In a study conducted in Uganda in 2002, the cost per test using RDT 
(Paracheck Pf) was USD 0.50 (Guthman et al 2002). Rolland et al (2006) also estimated 
the cost of Paracheck Pf to be USD 0.50. The differences in cost may be due to 
variations in suppliers and exchange rates across time and regions. Nonetheless, all these 
figures are more expensive than microscopy, which in 2000 prices was estimated to be 
about USD 0.12 to USD OAO per test (WHO 2000c). Therefore, in as much as RDTs are 
viable, the cost of the test may be a barrier for some countries. In Zambia, the current unit 
cost per Paracheck Pf test is estimated at USD 1.50. 
The other important disadvantage of RDTs, especially if HRP-2 based antigen is used, is 












problem for high endemic areas where drug resistance may be suspected, while in the 
actual fact, the RDT may pick the antigen released form already dead parasites (WHO 
2000c). This may lead to overestimation of treatment failures and lead to indiscriminate 
use of second line antimalarials such as quinine. The consequences of over treatment 
have been outlined by Amexo et al (2004) to be inflating of the drug budget and 
encourage the emergence of drug resistance due to increased drug pressure. Therefore 
HRP-2 based antigens are not useful in assessing drug efficacy but their use could be 
limited to detection ofnew cases ofmalaria. 
Other cases in which RDTs are prone to false positives have been said to be when 
gametocytaemia is high (WHO 2000c, Hanscheid 2003). This is termed false positive 
because the gametocytes do not lead to clinical disease and are usually not cleared by 
antimalarials that target asexual parasites (WHO 2000c). 
The other limitation of using RDTs has been reported to be the inability of obtaining 
quantitative information (WHO 2000c). An RDT will only detect if parasites are present 
or not but may not provide insight into the level of parasitaemia. Knowing how much 
parasitaemia is present has implications for diagnosing severe malaria. Another 
disadvantage is the inability to differentiate among species except for Plasmodium 
Jalciprum (WHO 2000c). 
There are various brands of commercially available RDTs, which use either the HRP-2 or 
the pLDH antigen detection methods. These are: 
• 	 Paracheck Pf, ParaSightF, ParaHITf, ICT Pf or PflPv and PATH Falciparum 
Malaria IC test. These tests use the HRP-2 antigen. 
• 	 OptiMal and KAT use the pLDH antigen. 
Even though the brands are different, the evaluations are usually conducted based on the 












HRP-2 based RDTs have been evaluated in various countries in comparison with 

microscopy. In a study by Mendiratta et al (2006) in India, 443 patients were diagnosed 

using RDTs (Paracheck Pf) and microscopy (read by two independent microbiologists). 

Paracheck Pf. was found to have a sensitivity of 92.6% and 98.6% specificity. The false 

negatives by were found to be in 7,4% of the samples. Singh et al (2005) also assessed 

. the usefulness of RDTs (Paracheck Pf and ParaHITf). Paracheck Pf was more senisitive 

(93%) than ParaHITf (87.5%) in detecting placental malaria.Thesed studies showed that 

concluded that detection of malaria using HRP-2 based RDTs might have a role in 

routine diagnosis. However, clinical diagnosis may override a negative RDT result if 

malaria is strongly suspected. 
In Uganda, a high transmission area, Guthman et al (2002) conducted an outpatient-based 
assessment of RDTs in comparison with microscopy. 742 patients who were clinically 
suspected to have malaria were enrolled. Paracheck Pf was not only found to be highly 
sensitive (97%) but was also reliable, user friendly and relatively cheap (USDO.5 per 
test). The sensitivity of Paracheck Pf was higher than that of ParaSight F (88.9%), which 
was found by Shiff et al (1993) in a high transmission area in East Africa. In the 
Tanzanian study, Shiff et al 1993 also demonstrated the extent to which HRP-2 antigens 
persist in the blood of treated patients. Ten days after treatment, it was found that 10% of 
those treated still tested positive and this persisted up to 14 days after treatment. 
Nonetheless, the test was said to be accurate enough to warrant its use in rural centres 
where microscopy services are not available. 
Other studies have evaluated RDTs in the context of special groups such as refugees and 
travellers returning from endemic countries. In Cambodia, Causer et al (2005) evaluated 
the role ofRDTs in a refugee setting. 902 refuges were screened for malaria using RDTs, 
microscopy and PCR. When compared with microscopy, RDTs were found to be 100% 
sensitive and 99% specific at a prevalence of 1 %. They further observed that RDTs were 
useful in providing timely, sensitive diagnosis and treatment in a refugee setting. In 
Honduras, Palmer et al (1998) evaluated the performance of an OptiMal test in an 












identified to be the causal agents. For P. Jalciparum, OptiMal was found to be 94% 
sensitive and 99% specific whereas for P. vivax sensitivity was 88% and specificity was 
100%. Based on these findings, it was concluded that OptiMal tests could be useful in 
detecting malaria in epidemic situations. 
Marx and colleagues (2005) conducted a meta-analysis of RDTs in travellers returning 
from endemic countries. They reviewed studies, which were looking at diagnostic 
accuracies in non-immune patients with microscopy as the gold standard and stratified 
results into either antigens group (HRP-2 or pLDH). After reviewing 21 studies they 
found that HRP-2 based assays were more accurate than pLDH assays. They also found 
that there was more evidence regarding Plasmodium Jalciparum species than the other 
three (malariae, ovale and vivax). This may be due to the fact that most malaria is caused 
by P falciparum species hence the concentration of research in this area. 
Buchachart et al (2004) evaluated the performance KAT (pLDH-based) in diagnosing 
malaria as compared to microscopy in a hospital setting. The KAT test was found to have 
a sensitivity of 96% and 92% specificity in diagnosing both falciparum and non­
falciparum species (mixed infections). In Kuwait, two commercial assays (leT Malaria 
Pf/Pv tests and OptiMal) with expert microscopy for malaria diagnosis in local health 
centres among 750 participants (Iqbal et al 2002). The specificities for both tests were 
found to be 98%. The sensitivities varied depending on the species. They also reported 
that when parasite density decreased to less than 5001 microlitre of blood, the sensitivity 
of both tests was reduced. pLDH based performed better than HRP-2 based assays. This 
conforms to observations that RDTs sensitivity is reduced in very low parasite density 
(WHO 2000c, Palmer et al 1998). 
In the Philippines, trials were performed among health workers in a remote area 
comparing clinical diagnosis, RDTs (leT Pf/Pv) and local microscopy (Bell et al 2001). 
The three approaches were compared to 'expert microscopy'. leT Pf/Pv tests were found 
to be 97.9% sensitive, clinical diagnosis was found to be 95.4% sensitive but only 16.5% 












microscopy was detected by RDT. An assessment of local health workers (non-medical 
workers) found that they were able to accurately perform ICT PflPv tests after a brief 
training on how to use the malaria test. These observations are important in 
demonstrating the role ofRDTs at low levels ofhealth care. 
Other factors which have been assessed with regard to RDTs in the degree of agreement 
among different users and the occurrence of false negatives. Lema et al (1999) showed 
the high degree of agreement (99%) among five different microscopists. Mills et al 
(1999) compared the accuracy of RDTs (PATH Falciparum Malaria IC Strip) with 
microscopy and PCR. They found that false negatives were likely to occur in samples 
with less than 100 parasites per micro litre ofblood. 
3.5 Economic Evaluations in Malaria Control Including Malaria Diagnosis 
As pointed out by Foster and Phillips (1998) the role of economics in malaria control is 
by far and large becoming useful in providing insights for decision-making. The increase 
in the burden of disease not only impacts negatively on potential economic gains due to 
absenteeism from school and work (Breman et al 2004, Utzinger et al 2002) but it also 
increases costs for the health systems. More so in third world countries, which are said to 
be struggling to meet the need for increased funding of health programmes (Yeung et al 
2004, De Savigny and Binka 2004). Evans and Hurley (1995) have stated that, the lack 
of adequate resources to meet the increasing demand entails making choices among 
competing interests to achieve desired goals. 
Furthermore, the discovery of new technologies for malaria control is also coming at a 
greater cost. Goodman et al (1999) have observed that more effective interventions are 
seemingly expensive to implement. This situation is currently being experienced in 
Zambia where for instance, there has been an eight-fold increase in the malaria drug 
budget. This was mainly due to changing the first line treatment from SP to AL (Personal 












important to establish whether such budgetary expenditure is translating into more health 
effects. Such is the role ofcost effectiveness analysis in health care. 
Cost effectiveness analysis (CEA) is a form of economic evaluation in which the costs 
and effects of specific interventions are evaluated jointly. Thus, cost effectiveness ratios 
refer to the cost for a unit of effect. For example, cost per malaria case detected or cost 
per malaria case prevented. Note that the methods for economic evaluations are reviewed 
in details in chapter 4. 
Various studies have been conducted in SSA to show the cost and cost-effectiveness of 
malaria control interventions such as vector control and case management options. In a 
community randomised control trial in India,Bhatia et al (2004) compared the cost 
effectiveness ofIRS and ITNs in a low malaria endemic area. The cost per case prevented 
was found to be lower for ITNs (USD 52) than IRS (USD 87). In another cost 
effectiveness study in Kwa Zulu Natal (South Africa) AL was compared with SP for 
malaria treatment from a providers' perspective (Muheki et al 2004). It was found that 
the cost per malaria out patient visit was USD 9.77 when using SP and USD 17.38 for 
AL. Further, using a decision tree analysis model; the average cost per life saved was 
almost 9 times lower for AL (USD 18) than SP (USD 158). 
Goodman et al (1999) conducted a modelling of the cost effectiveness of malaria control 
interventions based on a hypothetical setting. They found that the cost per DALY averted 
was USD 19-85 for ITNs, USD 32-58 for IRS conducted twice a year, USD 3-12 for 
children chemoprophylaxis, USD 4-29 for IPT in pregnancy and USD 1-8 for improved 
casemanagement. 
In Thailand, Kamolratanakul et al (2001) compared the cost effectiveness of malaria 
prevention (ITNs and DDT) with surveillance in a malaria endemic area. The cost of 
preventing a case of malaria using ITNs was found to be USD1.54, whereas that of DDT 
was found to be USD1.87 per case prevented. However, when compared to control areas 












and ITN) were more cost-effective since surveillance attracted a cost of USD2.50 per 
case prevented. Based on these results, malaria prevention is more cost-effective than 
surveillance in malaria endemic areas. 
Goodman and Mills (1999) conducted an extensive review of 14 studies, which were 
addressing the cost effectiveness of malaria control interventions. Among the fmdings, it 
was observed that improving treatment was highly cost effective. These observations may 
be attributed to the preventive and curative effects of treatment. In curing the patient, 
morbidity is reduced (and finally mortality is prevented) and hence increases the number 
of cases successfully treated. But also the treatment given to the patient reduces parasite 
pool available for transmission to other uninfected individuals. 
Rajab et a1 (2005) conducted cost effectiveness evaluation of pre-transfusion screening of 
donor blood when compared to antimalrial prophylaxis of recipients. The study was 
conducted in both low and high transmission areas. The outcome measure was the 
prevalence of malaria in donor units. It was found that pre-transfusion screening was 
more cost effective than prophylaxis with SP. The former had a cost of USD 0.03 per 
case prevented, whereas prophylaxis costs per case prevented were USD 0.69 for children 
and USD 1.4 for adults. However, using ACT for prophylaxis instead of SP increased the 
cost of preventing malaria to about USD 7.79 for adults and USD 5.84 for children. 
Screening blood units for malaria prevented the disease in the recipient at a far much 
lower cost than prophylaxis and much more if the drug of choice was ACTs. 
In Guinea, Jha et a1 (1998) conducted a cost-effectiveness evaluation of forty health 
interventions from a provider's perspective. These interventions included prevention and 
treatment in primary and secondary care. The final outcome measure was life year saved. 
They found no systematic difference in costs by level of care. Among the interventions 
evaluated, IMCI for pneumonia, malaria and diarrhoea (proxy for clinical diagnosis of 
malaria) had a cost effectiveness of USD 8 per life year saved. Treating paediatric 
malaria was USD 13/life year saved and outreach programmes for ITNs were found to be 












was more cost effective than using ITNs in this context. They suggested an increase in 
govemment expenditure on health if health objectives were to be achieved. However 
comparing these results to other settings is difficult due to the use of different outcome 
measures. 
Rolland et al (2006) carried out a study to evaluate the cost effectiveness of RDTs 
(Paracheck Pf) in comparison with presumptive treatment (clinical diagnosis). They used 
a hypothetical epidemic setting with a cohort of 10,000 febrile patients in a month. The 
treatment options were either Artesunate-amodiaquine (AS+AQ) or AL and three malaria 
prevalence levels were assumed (25%,50% and 75%). The main outcome measure was 
incremental cost per false positive averted, and the secondary outcome measure was cost 
per true malaria case detected. The cost per true malaria case detected was found to be 
similar with either treatment options and at all levels of prevalence. RDTs however, were 
found to be more cost effective at reducing false positives in the AL treatment option (at 
prevalence less than 75%). But it was less effective in the AS+AQ option at all the three 
prevalence levels. The RDT strategy was found to have a positive incremental cost at a 
prevalence of 21 % or higher for artesuante amodiaquine and 55% or higher for AL. 
However, this threshold increased to 58% and 70% respectively if an incremental cost of 
€1 per false positive averted was tolerated. These findings suggest that the cost 
effectiveness of a diagnostic strategy would be affected by malaria prevalence, the cost of 
the drug and the cost of the diagnostic strategy. As reported elsewhere (Lee et al 2002) 
the usefulness of new diagnostic technologies will depend on the cost, ease of use, 
specificity and sensitivity, time, purpose and setting. 
However, researchers have expressed concern on the lack of consistency in methods and 
outcomes used in cost effectiveness analysis (Goodman et al 1999). This tends to limit 
the external validity of study fmdings. They have also observed that many interventions 
suffer from a lack of information on costs and effects. It is therefore difficult to compare 
results from different studies and across countries. Furthermore, Goodman et al (1999) 
have also argued that factors such as disease transmission patterns, price of commodities, 











intervention. They also pointed out that even though an intervention is proved to be cost 
effective, the operational and fmandal feasibility might affect its implementation. 
3.6 Summary ofthe Evidence 
It is evident from the literature that an enormous body of information exists on malaria in 
general. This is because malaria has continued to be a priority public health problem due 
to failures of eradication campaigns, its complexity and high control costs. The level of 
poverty in the regions where the disease is prevalent exacerbates the situation. 
Malaria diagnosis still remains a challenge under current health system structures. 
History shows a heavy reliance on microscopy in health facilities and yet these services 
are unavailable to most people who need them. The inputs required for setting up a 
functional malaria laboratory represent a considerable financial burden. New 
techuologies to complement microscopy services have been developed. However, these 
are met with issues of cost, accuracy and malaria endemicity. Clinical diagnosis of 
malaria, though widely practised, has led to overestimation of the disease burden and is 
costing health systems potentially avoidable drug costs. The consequent result of this 
practice is poor patient management. 
Despite the relatively wide range of studies on economic evaluations in malaria, those 
specifically addressing malaria diagnosis are rare. In the case of Zambia, no such studies 
were available. This gap in information needs to be addressed seeing that the role of 
economics in malaria is vital. More especially that policy decision-making needs to be 
based on evidence. Table 3.3 summarises the evidence on the sensitivity and specificity 
of each of the three diagnostic strategies. This particular evidence was selected to 
represent the values, which will be used in the analysis of this study. The sensitivity and 
specificity was chosen from settings similar to the Zambian context in terms of type of 
diagnosis strategy and the level of malaria transmission. These studies were further 
considered because expert microscopy was used as the gold standard. The studies on 











different sets of findings. Studies, which compare basic microscopy tests to expert 
microscopy, are rare and so only one could be accessed (Colin et al 2002). For the RDT 
strategy, the studies specifically using Paracheck Pfwere selected since this is the type of 
RDT, is currently in use in Zambia. 
Table 3.3 Summary of Reported Sensitivity and Specificity of Malaria Diagnosis 
Strategies 
Diagnosis Sensitivity Specificity Sample Source 
Strategy % % 
Clinical 100 63 438 Hozhabri et al 2002, Pakistan 
93 15.5 395 Tarimo et a12001, Tanzania 
83 75 1245 Muhe et al 1999, Ethiopia 
51 60 1245 Muhe et a11999, Ethiopia 
80 32.9 1210 Ndhlovu et a12004, Zambia 
Microscopy 91 71 204 Colin et al 2002, Indonesia 
RDT 92.6 98.6 443 Mendiratta et al 2006, India 













4.1 Theoretical Background on Economic Evaluation 
Economic evaluation has been defined as "the comparative analysis ofalternative 
courses ofaction in terms ofboth their costs and consequences. "(Drummond et al 1987). 
Economic evaluation has gained considerable attention due to the scarcity of resources 
for health care (Evans and Hurley 1995). There are never enough resources to cater for 
the growing health needs of a population, which are further increased by technological 
development in the medical field. Economic evaluation use standardised methods to 
assess the relationship between resources for programmes and their outcome. Thus, 
economic evaluation in health care constitutes a relevant input in the policy process in 
terms of the efficiency implications ofaltemative health programmes. 
Efficiency in health care is used to determine how the given resources (inputs) are 
utilised to produce better health (output). There are two broad terms, which are used to 
define efficiency: technical and allocative efficiency. Technical efficiency determines 
whether the available resources are being used to maximise the desired outcomes (Palmer 
and Torgerson 1999). For example, if two diagnostic strategies A and B are compared, 
and it is found that B costs less per case correctly diagnosed than A, then B is said to be 
technically efficient. Thus measuring technical efficiency is applied to a situation where 
the programme of interest is already defined, but there is a need to determine how best to 
implement the programme. On the other hand, allocative efficiency considers the efficient 
allocation of resources across different interventions. Thus a programme is allocatively 
efficient if resources are allocated "to maximise the welfare of the community" 
(Drummond 1991). 
In economical terms, the term cost is defined as "the value ofresources used to produce 
something" (Creese and Parker 1994). The costs can be measured from two different 
perspectives: The societal perspective and the provider perspective. The societal 











costs) whereas the provider perspective only considers the direct costs to the programme 
(Schmid 1995). The costing perspective will determine which costs to include or exclude 
and how to further evaluate the costs (Luce and Elixhauser 1990). Costing involves a 
systematic identification, measurement and valuation of various resources for the 
programme under consideration. These resources can further be grouped by level of in 
put as capital or recurrent costs. Capital costs refer to resources, which last more than 
one year while recurrent resources last less than one year and are frequently purchased 
(Creese and Parker 1994). 
Outcome measures are concerned with the output of the intervention. Intermediate or 
final outcome measures can be used. Intermediate outcomes relate to those outcomes, 
which form part of the process that leads to improving health but are not in themselves, 
the final outcome (Evans and Hurley 1995). Examples of intermediate outcome measures 
include number of cases detected, number of ITN s distributed, number ofpatients treated, 
etc. Final outcomes measures on the other hand relate to the "final improvement in 
health" (Evans and Hurley 1995). These include indicators such as lives saved, deaths 
averted, DAL Y s prevented, Health Year Equivalent (HYE), or Quality adjusted life years 
(QALYs). HYEs, QALYs and DALYs are generic measures ofoutcome that combine life 
expectancy and quality of life in only one indicator. Generic measures of outcome allow 
direct comparisons to be made among different conditions or healthcare programmes. 
There are four main types of economic evaluation namely: Cost minimisation analysis 
(CMA), cost effectiveness analysis (CEA), cost utility analysis (CVA) and cost benefit 
analysis (CBA). All these methods use cost in monetary terms, the main difference lies in 
the approach to assess the outcomes. CMA and CEA use natural outcome measures 
which are disease specific while CVA uses generic natural outcome measures such as 
DALYs, QALYs, HYEs and CBA measures outcomes in monetary terms (Drummond 
et aI1987). CMA, CEA measure technical efficiency while CVA and CBA are concerned 











It is important to note that in economic evaluation, there has to be at least two 
interventions to be compared in terms of their inputs and outputs. These variables (inputs 
and outputs) can be measured in natural and monetary units depending on the form of 
evaluation. 
Some corrunon challenges in economic evaluations have been identified. These include 
methodological heterogeneity, lack of credible data for estimates of effectiveness 
(Hutubessy et al 2003) and where such data exists usually its from a trial setting which 
differs significantly from actual field setting (Drurrunond 1992). Differences in methods 
and study populations affect the extent to which findings of one study can be generalised. 
This is further compounded by differences in the costs of interventions in different 
settings (Briggs et al 1994). Nevertheless, these uncertainties in economic evaluation can 
be dealt with through sensitivity analysis. Sensitivity analysis explores how changes in 
different assumptions and specific parameters impact on the baseline results (see section 
4.9 below). 
To overcome some of these challenges just described above, a comprehensive economic 
evaluation is recorrunended . In an economic evaluation, the recorrunendation of an 
intervention will depend on the quality of the data used and the accuracy in the definition 
of various interactions. The latter can be health system and epidemiology related. The 
basic principles on how to conduct an economic evaluation as outlined in Drurrunonds et 
al (1987) are: 
The question under consideration needs to be specific as to what interventions are being 
compared and the possible outcomes. For example are bed nets more cost effective than 
IRS in preventing malaria cases? The alternatives to be evaluated need to be 
comprehensively described. This will favour potential applicability in other settings. The 
evidence on prograrrune effectives needs to be demonstrated; this implies that sample 











established. All relevant costs and consequences (according to the study perspective) 
need to be identified, measured and properly valued. In this stage, it is key to use the 
economic concept of cosl. Costs and consequences need to be adjusted by differential 
timing by discounting; this process is grounded in the principle of time preference. After 
the average cost per outcome is analysed, incremental costs and consequences need to be 
analysed. This allows measuring the additional costs required to produce additional 
outcomes. Sensitivity analysis is then performed on major variables to show changes in 
assumptions and parameters affect the results. Finally, the feasibility in tenns of 
financial, logistics and programme design is discussed to guide policy makers with a 
broad view of underlying factors. 
These steps are useful in guiding researchers on how best to conduct these evaluations 
and allow readers to assess the validity of their findings. Further it offers an opportunity 
for others to either adapt the findings or replicate the study in their specific context. 
4.2.0 Study Design 
4.2.1 TyPe ofEconomic Evaluation 
The study is a cost effectiveness evaluation of the malaria diagnosis alternatives in health 
facilities in Zambia. This study is concerned with technical efficiency rather than 
allocative efficiency. That is to say, malaria is already a health priority in Zambia. 
Therefore, this research aims to answer the question: Which is the most cost effective 
method to diagnose malaria in outpatient facilities in Zambia? There are three available 
options for malaria diagnosis (clinical, microscopy and RDTs) . These strategies have 
different capacities to correctly diagnose malaria cases as well as different costs. The 
outcome measure being used "the proportion of cases correctly diagnosed" is an 
intermediate one, which cannot be used either for cost benefit or cost utility analysis, 











4.2.2 Description ofInterventions Under Comparison 
The conceptual framework of malaria diagnosis in Zambia (as shown figure 4.1 below) 
presents no major departure from what is known in the literature. The strategies available 
for malaria diagnosis include: clinical , microscopy and RDTs. 
4.2.2.1 Clinical Diagnosis ofMalaria 
Firstly, when a patient arrives at the out patient department (ODP), the first point of 
contact is usually a nurse or a clinical officer (or a community health worker at some 
rural health centres and health posts). These are frontline health workers who have the 
capacity to screen patients and provide the necessary health services. In the case of a 
suspected malaria visit, a patient history of symptoms will be taken to ascertain the 
reason for the visit. The minimal requirements for this strategy of diagnosis are simply a 
thermometer (for measurement of axillary temperature) and a stethoscope where 
applicable. If temperature is above or equal to 37.5°C or where a history of fever exists 
and malaria is suspected, treatment is commenced and the patient returns home. Thus it 
is possible for a trained health worker to exclude fevers from malaria based on signs and 
symptoms the patient presents with . This allows the health worker to manage the case as 
non-malaria. Thus, it is possible to have cases found negative for malaria after clinical 
diagnosis. 
4.2.2.2 MicroscopvDiagnosis ofMalaria 
Where microscopy facilities were available, a clinical officer, nurse or a Commissioned 
Daily Employee (CDE) initially assessed patients. If malaria is suspected, the patient is 
sent to the laboratory for malaria investigation. The laboratory facilities are usually 
located within the clinic complex but in a different room or wing. At the laboratory, the 











infection. Once the laboratory investigation is complete, the results are recorded in the 
patients file and the patient is instructed to return to the screening room with the 
laboratory results . 
The clinician then is supposed to prescribe antimalarial treatment based on the laboratory 
result and the clinical presentation of the patient at that time. The inputs required for one 
patient to be microscopically examined for malaria parasites include: I clinical officer or 
nurse (3 - 15 minutes per patient), I trained microscopist or laboratory technician, 
laboratory space, a functional microscope, reagents, electricity supply, water supply and 
other consumables such as lancets, blood slides. Microscopy diagnosis results could be 
obtained after at least 30 minutes . 
4.2.2.3 RDT Diagnosis ofMalaria 
In the case of facilities with RDTs, the assessment of the patient is performed by either of 
the available health workers as mentioned above. Once malaria is suspected, 
parasitological confirmation of malaria infection is performed with an RDT. Depending 
on the results, the clinician may then prescribe an antimalarial. It should be noted here 
that the screening health worker performs both the clinical assessment and RDT. This is 
unlike in microscopy facilities where laboratory personnel are involved in the diagnosis 
of malaria. The minimum requirements for this diagnostic strategy are: 
I Paracheck Pf kit (which contains a test dip stick, desiccant, sample applicator, buffer 
solution and collection capillary tubes) and I clinical officer or nurse (or CHW in some 
rural areas) with minimum orientation on how to use the RDT. Lancets, methylated spirit 
and cotton wool were some of the supplies needed but did not come with the kit; they 











Figure 4.1 Conceptual Framework of Malaria Diagnosis in Zambia 





Malaria Diagnosis Test 	 Treat Presumptively 
(as malaria or non-malaria) 
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Microscopy 	 RDTs 




(Treat with antimalarial) Found Nr"iV< Found Positive (Treat with antimalarial) 
/~ 
True False True 
I ~ 
False 
Positive Positive Positive Positive 
Don't give antimalarial 
Assess other causes of fever 
False Negative, True Negative 
No other cause of fever, If symptoms persist, but slide still 
treat as malaria negative, no antimalarial treatment 
Among the three diagnostic strategies, clinical diagnosis is widely used, followed by 
microscopy and least of all RDTs (recently introduced). Microscopy centres are found 











small proportion of urban health centres. However, effective treatment in form of ACT 
(AL) is available countrywide. This treatment is more expensive than previously used CQ 
or SP . Guidelines for malaria diagnosis and treatment are available and are supposed to 
be the guiding principle in malaria case management. To ensure adherence to these 
guidelines, provincial health officers in each region have the mandate to carry out 
performance assessments in order to monitor health worker practices. In-service training 
and orientations are held from time to time to help sustain good clinical practice. A few 
health workers (33%) have also been trained in IMCl. 
4.3 Study Populations and Sample Size 
The analysis included all malaria related visits (suspected or confirmed), which occurred 
from March to November 2005 in 12 facilities in the four study districts . The 8-month 
study period was used because that was the available time frame for data collection in the 
districts under financial sustainability study (see section 4.4 below). This period captured 
both the low and high transmission seasons of malaria. Patients were stratified according 
to age, month of attendance and the diagnostic strategy used on the day of their 
consultation. There were no exclusions by age, sex and pregnancy status. In this study the 
term malaria may be used interchangeably when referring to either uncomplicated or 
severe malaria (unless explicitly stated otherwise). 
4.4 Study Sites 
The study was undertaken in four districts namely Chingola (Copperbelt Province), 
Kabwe (Central Province), Kalomo (Southern Province) and Chongwe (Lusaka 
Province). Malaria is meso to hyper endemic in these districts (National Malaria Control 
Centre 2001). In each of these districts, three facilities were used to collect data for the 
study, bringing the total of facilities sampled to 12. Table 4.1 below summarises the 











the sentinel sites surveillance system for malaria so the research findings will be 
representative of the various malaria epidemiological zones currently in Zambia. 
Table 4.1 Characteristics of Study Districts 
District Chongwe Chingola Kabwe Kalomo 
Province Lusaka Copperbelt Central Southern 
Setting Rural Urban Urban Rural 
Population** 157,664 196,685 196,828 181 ,379 
Total number of health 26 10 24 
fac iiities * * * 
Malaria Incidence/ l 000 
23 
129.8 56.57 111.45 80.76 
population **** 
Number of health facilities 2 4 5 2 
with microscopy services* 
Number of facilities with 42 4 1 
trained laboratory 
technicians* 
Number of facilities using 2 4 
RDTs* 
1 1 
Sources:*NMCC 2005, **DHS 2001-2002, ***CBOH 2002, ****HMIS 2004 (Malaria incidence 
refers to the number of new malaria episodes per thousand population) 
The districts and their respective facilities were purposively chosen because; they were 
part of the larger study collecting information on the "financial sustainability plan (FSP)" 
for scaling up malaria control activities. The FSP study is being developed by NMCC 
based on the recommendations of the MOH to identify resources needed and financing 
gaps for the malaria strategic plan to be implemented . This provided the means of 
collecting quality and reliable data from these facility registers under routine conditions. 
In the context of the FSP study, 3 facilities in each of the 6 districts were allocated to 











diagnostic tests. This diagnostic model was being piloted in these sites and not in the 
entire country. All the patients suspected of malaria were being recorded in the facility's 
outpatient malaria registers and received confirmatory diagnosis based on the allocated 
method in that facility. In all the six districts and country wide, AL was being used as 
first line treatment for malaria. However, due to resource constraints, data on costs, 
diagnosis and treatment were collected in four out of the six districts. The sununary of 
diagnostic strategies by district and facilities is shown in table 4.2 below. The defined 
catchment area of each facility is provided in brackets. 
Table 4.2 Summary of Diagnostic Strategies by Study Site 
DISTRICT FACILITY/DAIGNOSTIC TOOL 
(Catchment Area) 

























4.5 Data Collection 
Data was collected from primary sources as opposed to hypothetical settings, which have 
been widely used in economic evaluations through modelling (Hanson et al 2004, 
Goodman and Mills 1999). The advantage of field-based data is that it incorporates the 
inherent differences in practice, settings and seasons, which cannot be found in 
hypothetical or trial settings. This is cardinal because effectiveness data collected in trial 











Morbidity data (malaria suspected outpatient visits and confirmed malaria cases) was 
collected retrospectively using facility registers. Patients were diagnosed in each facility 
based on the diagnostic strategies being used. The type of treatment administered and 
laboratory related characteristics were also reviewed. Cost information was obtained 
from facilities , central level sources and suppliers of commodities where applicable. 
Secondary data from published literature was used to determine the sensitivity of clinical, 
microscopy and RDTs in diagnosing malaria. 
4.6.0 Costing Perspective and Approaches 
The costs were analysed from a providers ' perspective. This is because the cost of 
implementation of diagnostic services for malaria is largely borne by the health system. 
The basic health care package, which includes malaria, is provided for free especially in 
the lower level facilities where the data was collected (NHSP 2005). The ingredient 
approach combined with step-down approach to costing was used to estimate average 
costs per month and per year (Drummond et al 1987). 
Data collection forms (Appendix I) were developed to conduct inventories on capital and 
recurrent costs related to malaria diagnosis. Health staffs at each of these facilit ies were 
also interviewed to obtain information on the types and estimated quantities of resources 
they use in daily management of malaria patients. Financial reports, cash receipts, 
malaria outpatient registers, district action plans, procurement units, market prices of 
commodities and various data sources were reviewed for measurement and valuation of 
the resources used. Cost data, which was obtained from facilities related to expenditures 
that are managed by the peripheral centres and their respective district offices. 
However, full costs of salaries, unit cost of drugs and vehicles are usually purchased 
centrally and then distributed to the respective facilities. As such, such cost data was 











cost of distribution was estimated from main government distributors and was added to 
the unit cost. 
4.6.1 Capital Costs 
Capital resources (i.e. items which have a useful life of more than one year) were 
annualised based on the replacement value, its estimated useful life and the official 
discount rate used in Zambia (5%( This allowed the equivalent annual cost of 
equipment to be calculated (Johns et al 2003) . The useful lifespan of the different assets 
included can be seen in table 4 .3 below. Capital costs included: 
• Equipment (such as microscopes, furniture in laboratory and screening room, etc) 
• Vehicles (including motor bikes or bicycles) 
• Buildings (Laboratory, screening room and storage rooms) 
Table 4.3 Useful Life Span of Capital Costs 









Digital thennometer 3 
Training 5 
Source: BHCP 2005, Expert OpinIOn 
The allocation of capital costs to malaria diagnosis was done according to the utilisation 
rate of malaria OPD visits (see table 4.4). However, laboratory related capital costs such 
as a microscope and cost of a laboratory building were allocated based on the number of 











patients attending the laboratory for malaria as a proportion of laboratory visits for all 
other diseases. 
4.6.2 Recurrent Costs 
Personnel costs were measured based on number and categories of each type of staff 
(nurse, clinical officer, medical doctor, community health worker, etc) and their 
respective annual salaries. These were then allocated based on utilisation of facilities by 
suspected malaria patients (see table 4.4 below). The malaria cases reported for these 
facilities account for both con finned and unconfinned cases as captured by district 
information offices. 
Table 4.4. Allocation Factors for Each Facility Based on Malaria OPD Visits . 
District Facility Suspected Malaria All Diseases OPD Suspected Malaria 
OPD Visits* Visits as % of total OPD 
Chingola Kalilo 634 3093 20.5 
Kabundi 6306 27417 23 .0 
Kasompe 1604 6416 25 .0 
Chongwe Chinyunyu 3276 7254 45 .2 
Chongwe 8847 20087 44.0 
Chalimbana 4310 10448 41.3 
Kalomo Kalonda 4176 11926 35.0 
Mukwela 3733 8647 43.2 
Namwianga 11155 42569 26.2 
Kabwe Natuseko 3950 8831 44.7 
Kawama 2753 8311 33.1 
Makululu 4147 14301 29 .0 
Sources: District Information Offices. * Malaria related visits regardless of diagnosis 











The data presented in table 4.S above refers to all OPD visits from January to December 
for 200S . On average, facilities in Chingola district recorded the lowest proportions of 
malaria attendance at OPD. The highest attendance was recorded by facilities in 
Chongwe district. All the strategies had a mixture of both low and high malaria 
attendance at OPD. 
Some recurrent costs such as supplies, and utilities were valued using a step-down 
approach to costing and allocated based on facility utilisation by malaria patients. 
However, costs unique to malaria (such as cost of the diagnostic technique) were fully 
allocated as such. Further, the districts are also allowed up to IS% of their total 
expenditures on adrllinistration costs (or overheads). Therefore in the absence of better 
sources of adrllinistrative expenditures, it was assumed that on average, IS% of malaria 
related expenditure would be on administrative costs such as fuel, communications, 
cleaning materials, stationery and other utilities . For simplicity, all other recurrent costs 
(non-personnel or malaria specific) are termed overheads in this study. 
All prices in Zambian Kwacha were converted into United States Dollars (USD) 
equivalent using the existing average exchange rate of K4, 512.51 = 1usn for the data 
collection period March to November 200S (http ://www.aonda.com). The unit cost per 
patient was then derived for each diagnostic intervention. All the costs were analysed into 
averages per facility and strategy. 
4. 7 Outcome Measures 
A diagnostic test performed on a group of patients will give two categories of results : 
positive (those found with the condition of interest) and negative (those found not to have 
the condition of interest). However, since tests are not 100% accurate, an accepted gold 
standard is used as a comparator in order to evaluate how effective a test is at correctly 











the test results are then summarised into four categories: True positives, false positives, 
true negatives and false negatives (as shown in table 4.5 below). Thus in this study, 
malaria diagnosis accuracy of each technique was evaluated by its ability to increase 
cases correctly diagnosed (true positives and true negatives) and the ability to decrease 
cases incorrectly diagnosed (false positives and false negatives). These were calculated 
from the total number of patients screened, the screening results, the underlying malaria 
prevalence and sensitivity of the diagnostic strategy used . Table 4,5 below shows the ' 2 
x 2 Table' (which is based on Bayesian theory applied on screening methodology) used 
to carry out these calculations. 
Table 4.5 '2 x 2 Table' for Assessing Sensitivity and Specificity 




Positive True Positive False Positive 
Negative False Negative True Negative 
Total True Positive + 
False Negative 
False Positive + 
True Negative 
The main outcome measure was the number and proportion of malaria cases correctly 
diagnosed by each diagnostic strategy. To estimate the number of cases correctly 
diagnosed by each diagnosis strategy, evidence from the literature (see table 3,3 in 
section 3,7) was weighted up according to sample size and relevance for the Zambian 
setting. For the purpose of this study, sensitivity was used as the input variable, whereas 
specificity was an output variable . This is because sensitivity and specificity vary with 
prevalence, and the districts under study had varying underlying prevalence as shown in 
table 4.6 below. For clinical diagnosis, the sensitivity for two sites (Kalilo and Kalonda) 











positive for malaria. For the remaining two clinical sites (Chinyunyu and Natuseko), 
which at least reported on some negative cases, the average sensitivity was assumed at 
about 90%. These figures were similar to sensitivity analysis from literature (Hozhabri et 
al 2002, Tarimo et al 2001). 
Microscopy is assumed to be the gold standard only under ideal conditions. However, 
routine microscopy in itself has been found to have sensitivity of 91 % and specificity of 
71 % (Colin et al 2002) when compared to expert microscopy. Therefore, when 
determining cases correctly diagnosed, the sensitivity of microscopy evaluated was based 
on the trial results of Colin et al (2002). 
For RDT tests, the weighted average of the sensitivity was calculated from studies that 
used Paracheck Pf brand and performed field evaluations by comparing RDT to expert 
microscopy (Guthman et al 2002, Mendiratta et al 2006). The sample size of each study 
determined the weight used in the calculation of the average sensitivity. The two studies 
were selected based on clinical and methodological similarities. In this way, it was hoped 
that statistical heterogeneity would be reduced. The weighted average sensitivity for RDT 
was 95.36%. 
The underlying prevalence in the districts was obtained from survey data conducted by 
the NMCC. These surveys are conducted as part of the malaria information systems 
monitoring system and the REM surveys. The surveys use standardised methods and 
sample sizes. An important aspect of these surveys is that they incorporate the 2-9 years 
who are the standard group for estimating malaria parasite prevalence (NMCC REM 
Survey 2005 Report). In the case of Chongwe, Kabwe and Chingola, the prevalence 
figures were obtained from the 2005 parasitological surveys, whereas for Kalomo, the 
2004 figure was used in the absence of any latest estimates. The prevalence for each 
district was estimated to be 22.0% (Chongwe), 10.6% (Kabwe), 18.8% (Chingola) and 
26.3% (Kalomo). These prevalence values are assumed to approximate the true arumal 











Thus based on the sensitivity of each strategy and the underlying prevalence in each 
district, the following equations (derived from Bayesian theory) were used to estimate 
true positives, false positives, true negatives and false negatives and consequently the 
total negative and positive: 
1. True positives = prior prevalence * visits * sensitivity 
2. False positives = found positive - true positives 
3. False negatives = (prior prevalence * total visits) - true positives 
4. True negatives = found negative - false negatives 
5. Cases correctly diagnosed = true positives + true negatives 
6. Accuracy = number of cases correctly diagnosed/total visits . 
After obtaining the main results, other variables of the tests were estimated such as 
specificity and likelihood ratios. Likelihood ratios measure the probability that a given 
test result (positive or negative) would be expected in a patient with the condition of 
interest compared with the probability that the same result would be expected in a patient 
without the target disorder (www.cebm.netllikelihood-ratios.asp). Thus; 
7. Specificity = true negative / (false positive + true negative) 
8. Likelihood ratio positive = sensitivity/(l-specificity) 
9. Likelihood ratio negative = (l-sensitivity)/specificity 
A diagnostic test translates a pre-test probability (prior prevalence) of a condition in the 
population into a post-test probability on an individual patient. The direction and strength 
of the post-test probability depends on the sensitivity and specificity of the test. Post- test 
probability was estimated by applying the prior prevalence and likelihood ratios to the 











4.8 Average Cost Effectiveness and Incremental Cost Effectiveness Analysis 
After establishing the costs and consequences of each alternative, the average cost per 
case diagnosed as well as the average cost per case correctly diagnosed were calculated 
for each strategy. Average costs were calculated with and without treatment costs. 
However, the relevant cost effectiveness ratio has been defined as the average cost per 
case correctly diagnosed and treated, as follows : 
I. 	 Cost per case correctly diagnosed (CCD) = [Cd + Cd / CCD. Where, 
Cd 	 = Cost of diagnosis 
C l 	 = Cost of all treatment 
CCD 	 = Number of cases correctly diagnosed. 
2. 	 The incremental cost per additional case correctly diagnosed was calculated 
based on the changes in the costs and effects of moving from the strategy that 
costs less per patient diagnosed to the next alternative in order of the rank of 
costs per patient. 
Thus: 	 lCER = change in cost! change in cases correctly diagnosed. 
4.9 Sensitivity Allalysis 
Sensitivity analysis in economic evaluations is a way of handling uncertainties, which 
arises form various assumptions in the input variables for costs and effects . There are 
various types of uncertainties, which have been described in literature. These relate to 
data requirements , extrapolation, generalisability and analytic methods (Briggs et al 











Briggs et al (1994) have outlined four major forms of sensitivity analysis. These include 
simple sensitivity analysis, threshold analysis, extreme scenario analysis and probabilistic 
analysis . In this study, simple sensitivity analysis will be used to measure uncertainty. In 
this study, simple (one-way) sensitivity analysis will be used on parameters such as 
discount rate, sensitivity value of clinical diagnosis, accuracy of diagnostic tests, 
personnel costs, allocation factor, and changing the unit costs of RDTs and AL. The 
ACER will be recalculated according to the observed treatment practices. It has been 
demonstrated elsewhere that some of these variables might impact on results of a study 
(Drummond et al 1987, Rolland et al 2006, Creese and Parker 1994). Furthermore, 
personnel costs were chosen as a variable for sensitivity analysis because they were a 
major cost component in all the facilities . 
4.10 Data Entry and Analysis 
The data collected for this study was entered into two software. Morbidity data was 
entered and analysed in STATA version 8. Cost data was entered and analysed in excel 
based on principles of cost analysis (Drummond et al 1987, Creese and Parker 1994) as 
described in section 4.6 above. The number of cases correctly diagnosed for each 
intervention and the proportion of false positives and false negatives were calculated 
from the '2x2' table using the equations already defined in section 4.7 above. The cost of 
treatment was estimated from the unit cost of antimalarials and the number of patients 
treated by each type of antimalarial. The cost of implementing the most cost effective 
strategy was analysed based on implementing the most cost effective method on the 
already existing structures and resources . Sensitivity analysis was performed on various 
variables as mentioned in section 4.9. Table 4.6 below summarises the various 











Table 4.6 Parameter Assumptions and Data Sources 
Description Assumption Source 
Exchange Rate 
(8- month average) 
lUSD = ZMK4512.51 http://www.aonda.com 
Discount rate 5% MOH Planning Unit 
Overhead costs 15% 
(Of district recurrent expenditure) 
District Health Office (DHO) 
Personnel costs Gross earnings 
(Taken from central level) 
MOHIDHO 
Cost of drug AL = 2.45USD 
SP = 0.18 USD 
Quinine= 0.84 USD 
NMCC, (weighted average 
cost per person/course 
including storage and 
distribution costs). 
Cost/test RDT = 1.50USD 
Microscopy = 1.00 USD 
NMCC (excludes personnel 
and capital costs) . 
Laboratory utilisation 60% Expert opinion 
Sensitivity (clinical) 100%,90% Current study data from 
clinical sites and Hozhabri et 
al 2002, Tarimo et a12001. 
Sensitivity (microscopy) 91% Colin et al 2002 
Sensitivity (RDTs) 95.4% Guthman et al 2002, 
Mendiratta et al 2006 . 
Prevalence (Chingola) 18 .8% NMCC 2005 
Prevalence (Chongwe) 22.0% NMCC 2005 
Prevalence (Kalomo) 26.3% NMCC 2004 
Prevalence (Kabwe) 10.6% NMCC 2005 
Note: The malaria prevalence refers to the proportIOn of people wIth detectable malana 
parasites in their peripheral blood, approximated from the average annual parasite 













5.1 Summaries (rom Morbiditv Data 
Between March and November 2005, more than 23,600 suspected malaria visits were 
made at the 12 out-patient clinics in the four districts. Of these reported attendances , 6520 
(28%) were at clinical facilities. 10460 (44%) visited microscopy facilities and 6685 
(28%) visits were made at the RDTs facilities. Table 5.1 shows the aggregated diagnostic 
results for the entire study period per each facility. The highest number of malaria related 
visits were recorded at Natuseko health centre (3661) in Kabwe district. On the other 
hand, the lowest number of malaria attendances was found at Kalilo health centre in 
Chingola (409). Children under five years accounted for 51.08% of all attendances. 

















Kalilo 409 378 29 2 0.49 Clinical 
Kabundi 3084 1552 15 1517 49.19 Microscopy 
Kasompe 1187 281 6 900 75.82 RDT 
Chongwe 
(Rural) 
Chinyunyu 1430 1367 II 52 3.64 Clinical 
Chongwe 3338 1130 46 2162 64.77 Microscopy 
Chalimabana 2634 928 35 1671 63.44 RDT 
Kalomo 
(Rural) 
Kalonda 1020 1018 2 0 0.00 Clinical 
Nam wianga 1975 8 13 0 1162 Microscopy58.84 
Mukwela 874 263 I 610 69.79 RDT 
Kabwe 
(Urban) 
Natuseko 3661 3003 21 637 17.4 Clinical 
Makululu 2063 282 0 1781 Microscopy86.33 
Kawama 1990 216 I 1773 89.1 RDT 
TOTAL 23665 11231 167 12267 51.84 -
Overall, regardless of diagnostic strategy, 51.84% (N=12,267) were found not to have 











malaria, 98.5% were considered to be uncomplicated malaria and 1.5% (N=167) were 
diagnosed with severe malaria . 
When the cases were stratified by diagnostic method, there were significant differences in 
the proportions of uncomplicated and negatives malaria cases, especially between clinical 
compared to microscopy and RDT. The overall proportion of patients found negative 
with clinical diagnosis was 11 %, 63% with microscopy and 74% with RDT diagnosis. 
Severe malaria was diagnosed in 1 % of those diagnosed clinically and 0.6% in both 
microscopically and RDT diagnosed patients respectively. Figure 5.1 shows the overall 
diagnosis results per diagnostic method. 























The proportions of clinically diagnosed malaria were more than that diagnosed by either 
RDT or microscopy. 
Among the total attendances recorded in all the 12 facilities, 60.5% of the severe cases 











figure 5.2 below). This showed that malaria was more prevalent in the under five children 
than in those over five years of age. 















Negative Uncomplicated Severe 
5,953 10J 
The proportion of suspected malaria visits in relation to the catchment population was 
found to differ among facilities. Facilities in Chingola district recorded the least malaria 
related visits, while the rest were relatively similar (see table 5.2 below). 
Looking at facilities individually, Chalimbana recorded the highest proportion of 
suspected malaria visits per catchment population (40%), while the least malaria related 
visits were recorded in Makululu (7%). There was no clear relationship between malaria 
visits per catchments population by either setting or diagnosis strategy. However, it 
should be noted that two facilities (Kabundi and Kasompe) in Chingola and one facility 
in Kabwe (Makululu) are located in areas where vector control using IRS is being 
conducted. This may explain the relatively lower malaria related visits per population. 
Additionally, these districts are also located in the urban parts of the country where 
























Kalilo 5212 409 8 Clinical 
Kabundi 31857 3084 10 Microscopy 
Kasompe 14638 1187 8 RDT 
Chongwe 
(Rural) 
ChinY1!nyu 8281 1430 17 Clinical 
Chongwe 15486 3338 22 Microscopy 
Chalimabana 6596 2634 40 RDT 
Kalomo 
(Rural) 
Kalonda 4262 1020 24 Clinical 
Namwianga 6140 1975 32 Microscopy 
Mukwela 6140 874 14 RDT 
Kabwe 
(Urban) 
Natuseko 10873 3661 34 Clinical 
Makululu 28951 2063 7 Microscopy 
Kawama 6886 1990 29 RDT 
TOTAL 145322 23665 16 -
The trends in the diagnosis of malaria cases for all the 12 facilities during the 8-month 
period are illustrated in figure 5.3 below. 
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As observed in figure 5.3, during March there were more cases of uncomplicated malaria 
(and severe malaria) found than at any other time. From June to August, the number of 
malaria cases reported by the facilities remained almost the same at just above 1000 
cases. During the hotter and dry months beginning September and October, the cases 
were observed to be generally lower than during the wetter months (March and April) . 
' Visits' in the figure above refers to the total number of suspected malaria visits in the 
facilities. 
In terms of seasons, November to April is referred to as the rainy season, May to August 
are cooler and dry months, while September and October are hot and dry months (ZDHS 
200112002). Therefore, the rainy season months are expected to have higher malaria 
transmission (with the peak April/May) than both the cooler and hotter months . The 
negative malaria cases were lowest around March, but increased steadily until about 
August and started to decline thereafter. 
Microscopically confirmed malaria cases showed characteristic peaks in March (48%) 
and May (as shown in figure 5.4 below). By June, the proportion of malaria began to 
reduce steadily and reached the low level in August, where only around 20% of suspected 
cases were confirmed as malaria . 
Figure 5.4 Microscopy Diagnoses ofMalaria Over Time 
Proportion 
Mar April May JW1e July Aug Sept Oct Nov 











Figure 5.5 below depicts the proportion of positive cases in each study facility where 
microscopy was being used . Kabundi (urban) and Namwianga (rural), which, are 
supposed to be located in low transmission districts, recorded higher proportions of 
malaria positive cases. This could be because reducing transmission leads to a consequent 
decline in partial immunity making the population more susceptible to malaria infection 
(Personal Communication, Dr M. Kango, Malaria Case Management Specialist -
Lusaka). Chongwe (rural) and Makululu (urban) that are high malaria transmission areas 
recorded lower proportions of cases. On the other hand Kabundi and Makululu are both 
areas in which IRS is being implemented. 




lIE! Positive. Negative I 
The proportion of RDT confirmed cases showed a gradual decline from a higher number 
of cases in March to fewer cases in the drier and cooler months (see figure 5.6 below). 
This is very different from microscopy trends, which showed a peak in March and May. 
These differences could be attributed to differences in detection capacities of RDT and 
microscopy. Nevertheless, the trends in the transmission patterns by RDT confirmed 
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Chalimbana recorded a higher proportion of malaria than any other RDT site as shown in 
figure 5.7 below. Further Chalimbana also recorded the highest proportion of malaria 
related visits per catchment population (as shown in table 5.2 above). Kawama however, 
showed the lowest proportion of malaria cases despite the facility being located in an area 
said to be a high transmission area. One explanation could be due to the area being one of 
the few places in Kabwe where indoor residual spraying was conducted. However, as 
mentioned earlier, high transmission areas tend to have more asymptomatic cases. A note 
worthy feature is that Chalimbana also offers health services to some boarding schools 
and a teachers training college in the vicinity. So even if the catchment population was 
low, the actual number of patients seen from the college and boarding school might have 











Figure 5.7 RDT Malaria Diagnoses by Health Facility 
Proportion 
Kasompe ChaI.imbana Mukwela Kawama 
I[!ill Positive. Negative I 
The proportion of cases clinically diagnosed as malaria presented trends, which were 
different from those seen in microscopy and RDT sites. The cases seem too high all 
through out the study period (see figure 5.8). A slight decrease was noticed between April 
and July. However, on average the proportion of malaria cases were higher than 
expected. This general trend in the clinical cases affected the overall trend in all malaria 
cases as shown in figure 5.3 above (all cases over time). 
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Kalilo (99.5%) and Kalonda (100%) recorded the highest proportion of clinical cases 
than any of the other three clinical sites (see figure 5.9 below). Natuseko recorded a 
relatively lower proportion of malaria found positive than other facilities. Clinical 
diagnosis of malaria in these facilities led to all or almost all of the cases suspected of 
malaria being thought to have malaria . 
Figure 5.9 Clinical Malaria Diagnoses by health Facility 
10 
Proportion 5 
Kalilo Chinyunyu Kalonda Natuseko 
[ 0 Positive. Negative I 
The trends in malaria cases over time when stratified by diagnostic strategy are presented 
in figure 5.10 below. RDT and microscopy showed almost similar trends with a peak in 
the wetter months and lesser cases in the cooler and drier months. Clinically diagnosed 
























Figure 5.10 Trends in Malaria Cases Over Time by 
Diagnostic Strategy 
-+- Microscopy 















5.2 Number ofCases Correctly Diagnosed 
The number of cases correctly diagnosed by each strategy was calculated using the ' 2x 2 
table' shown in table 4.5 in methods section. In this section the details of these 
estimations are shown for each of the facilities as well as the average according to the 
diagnostic strategy used. Note that this is based on the assumptions on the sensitivity of 
each diagnostic strategy, which in turn were based on the available studies as shown in 
table 4.6 (methods section). 
Table 5.3 Cases Correctl;z: Dia~osed ~CCD1 b;z: Clinical Strate~ 
Kalilo Kalonda Chinyunyu Natuseko Total 
Visits 409 1020 1430 3661 6520 
Test Results 
Found Positive 407 1020 1378 3024 5829 
Found negative 2 0 52 637 691 
Estimations of Accuracy 
True Positive 77 268 284 348 977 
False Positive 330 752 1094 2676 4852 
True Negative 2 0 21 598 621 
False Negative 0 0 31 39 70 
CCD 79 268 305 946 1598 
Accuracy % 19.3 26.3 21.3 25.8 24.5 











The average accuracy (proportion of cases correctly diagnosed out of all diagnoses) of 
malaria diagnosis among clinically diagnosed patients was found to be 24.5%, as shown 
in table 5.3 above. This means that for every 10 malaria suspected patients clinically 
diagnosed, the number of cases correctly diagnosed would be less than 3. The highest 
accuracy of clinical diagnosis was found in Kalonda (26.3%) and the lowest was in 
Kalilo (19.3%). On average 17% of the patients clinically diagnosed to have malaria 
would actually have it. Conversely, about 10% of the patients who were found not to 
have malaria by clinical diagnosis would have had malaria (false negatives). A 'real 
positive ' malaria case was as likely as a 'real negative' malaria case to be found positive 
when diagnosed clinically (Likelihood ratio= 1.05). 
The average accuracy of microscopy in diagnosing malaria patients was found to be 
about 79% (see table 5.4 below) . This proportion was more than that which was observed 
in clinical diagnosis but less than the accuracy of RDT diagnosis of malaria. About 51 % 
of the patients who were microscopically diagnosed to have malaria may not have had it. 
Similarly, around 2.8% of the patients who were diagnosed negative by microscopy 
technique may have had malaria . 
Table 5.4 Cases Correctly Diagnosed (CCD) by Microscopy Strategy 
Kabundi Namwianga Chongwe Makululu Total 
Visits 3084 1975 3338 2063 10460 
Test Results 
Found Positive 1567 813 1176 282 3838 
Found negative 1517 1162 2162 1781 6622 
Estimations of Accuracy 
Tnle Positive 528 472 668 199 1866 
False Positive 1039 341 508 83 1972 
True Negative 1465 1115 2096 1761 6437 
False Negative 52 47 66 20 185 
CCD 1993 1587 2764 1959 8303 
Accuracy % 64.6 80.3 82.8 94.9 79.4 












As shown in table 5.4 above, the diagnostic accuracy of microscopy was highest in 
Makululu (94.9%) and lowest in Kabundi (64.6%). Kabwe district (Makululu health 
facility) uses trained malaria microscopists as opposed to the conventional laboratory 
technicians. These microscopists receive a short course (one month) on basic malaria 
microscopy and are employed on a part time basis by the district office. 
Among the RDT diagnosed cases, the proportion of cases correctly diagnosed (accuracy) 
was found to be 91 % (see table 5.5). The highest accuracy among the RDT sites was 
found in Kawama (98.7%), while the lowest accuracy was found in Chalimbana (83.4%). 
Among the patients diagnosed by RDT, 8% were wrongly diagnosed to have malaria 
when they probably did not have had it. This was much less than any of the proportions 
found in both the microscopically and the clinically diagnosed cases. The proportion of 
false negatives diagnosed by RDT was found to be about 1 %. The variations in accuracy 
among the sites may be due to human errors during sample preparation and reading of 
results . The same brand of RDTs was used in all the facilities . 
Table 5.5 . Cases Correctly Diagnosed (CCD) by RDT 
KasomEe Mukwela Chalimbana Kawama Total 
Visits 1187 874 2634 1990 6685 
Test Results 
Found Positive 287 264 963 217 1731 
Found negative 900 610 1671 1773 4954 
Estimations of Accuracy 
True Positive 213 219 553 201 1186 
False Positive 74 45 410 16 545 
True Negative 890 599 1644 1763 4896 
False Negative 10 11 27 10 58 
CCD 1103 819 2197 1964 6082 
Accuracy % 92.9 93.7 83.4 98.7 91 
Prior Prevalence 18.8 26.3 22 10.6 18.6 
The aggregated results on cases correctly diagnosed by each strategy are summarised in 
table 5.6 below. The table also shows the average prevalence, likelihood ratios and post­











Table 5.6 Summary of Average Effectiveness of Each Strategy 
Strategy Clinical Microscopy RDT 
Total Visits 6520 10460 6685 
Test Results 
Found Positive 5829 3838 1731 
Found Negative 691 6622 4954 
Estimations of Accuracy 
True Positives 977 1866 1186 
False Positives 4852 1972 545 
True Negative 621 6237 4896 
False Negative 70 186 58 
Sensitivity (%)- input 93.3 90.9 95.3 
Specificity (%)- output 11.3 76.5 90 
Cases correctly diagnosed 1598 8303 6082 
Accuracy (%) 24.5 79.4 91.0 
Estimations of Reliability 
Likelihood ratio positive 1.1 3.9 9.5 
Likelihood ratio negative 0.6 0.1 0.1 
Positive post-test probability 17% 53% 70% 
Negative post-test probability 10% 3% 2% 
Clinical diagnosis of malaria was found to have very low accuracy in diagnosing malaria 
when compared to either microscopy or RDT methods. The proportion of false positives 
in clinical diagnosis was four times more than those by microscopy and nine times more 
than those observed by RDT strategy. As indicated in the table, the RDT diagnosis led to 
less false negatives «1%), while clinical and microscopy were responsible for 1.1% and 
1.8% false negatives respectively. A lower proportion of false negatives are desirable in 
malaria diagnosis due to the negative consequences of leaving malaria untreated. 
For clinical diagnosis likelihood ratio positive indicates that a 'real positive' malaria case 
was as likely as a 'real negative' malaria case to be found positive when diagnosed 
clinically (Likelihood ratio = 1.1). On the other hand, the likelihood ratio negative 
indicates that a 'real negative' malaria case was 0.6 times as likely as a 'real positive' 
malaria case to be found negative when diagnosed clinically. Thus, with clinical 
diagnoses a malaria case found positive will have only 17% probability of being truly 
positive. The clinical diagnosis translates the pre-test to post test probability of malaria in 












by a positive likelihood ratio of about I . Negative post-test probability indicates that a 
negative result on clinical diagnosis has a 10% chance of being a malaria case (false 
negative). 
A positive malaria case diagnosed microscopically will have a 53% certainty that it is a 
true positive malaria case, while a negative result is 3% likely to be a true malaria case 
(false negative). Thus a negative malaria result diagnosed by microscopy would be more 
reliable than a positive result. 
As shown in table 5.6 above, a positive malaria result on RDT has a 70% chance of being 
a true malaria case, while a negative result has only a 2% likelihood of being a true 
malaria case. Both the positive and negative likelihood ratios of the RDT test were high 
indicating that a malaria test result on RDT is more reliable. 
5.3 Cost ofMalaria Diagnosis for Each Strategy 
The costs of malaria diagnosis were grouped into five main categories. These were 
personnel, capital costs , diagnostic teclmique and overheads. At this stage treatment cost 
had not been included. These categories were further specified for each diagnostic 
strategy and facility. All costs are expressed in USD. In each table the catchment area 
and total visits (malaria suspected) have been added so that total costs can be related to 
utilisation and total inputs. 
Table 5.7 below shows the estimates in costs for clinical diagnosis sites. The major cost 
components for clinical diagnosis of malaria were personnel (83%) and overheads (13%). 
The later included administrative costs and utilities such as water, electricity and 
telephone bills. In all the four clinical sites, personnel costs were by far the highest 
contributor to malaria expenditure, accounting for an average of 83%. Non- laboratory 
related capital costs were the least contributor to clinical diagnosis of malaria. There were 











Table 5.7 Cost Estimates for Clinical Diagnosis (in USD) 
Kalilo KalondaChinyunyu Natuseko Total 












Utilisation rate (b/a} 0.08 0.24 0.17 0.34 0.23 
Costs 















Total costs 1,226 1,618 4,282 10,737 17,864 0/0 
Unit cost per type of resource 

Personnel 2.4 1.3 2.4 2.5 2.3 83% 







Overheads 0.4 0.2 0.4 0.4 0.4 13% 

Cost ~er visit 3.0 1.6 3.0 2.9 2.7 100% 

The average cost of clinical diagnosis of malaria was USD 2.7 per patient (ranging from 
USD 1.6 to USD 3) as shown in table 5.7 above. Kalonda was found to have the lowest 
cost per visit. However, the remaining three facilities had similar costs per patient despite 
having different catclunent populations and utilisation rates. 
As shown in table 5.8 below, personnel costs were a major cost contributor to microscopy 
malaria diagnosis (65%). The highest personnel related costs per visit were found in 
Kabundi (urban) and Chongwe (rural). These sites had more health workers than any of 
the other two sites and on average more than any of the clinical and RDT sites. 
Namwianga health centre was associated with lower costs, which can be partly explained 
by its highest utilisation rate and low expenditure in personnel. 
Diagnostic specific costs (recurrent and capital costs) accounted for 14% the total costs as 
shown in table 5.8 below. Overheads expenditure was 13% of the total costs. 
Microscopy sites tended to have more resources than the clinical and RDT sites. This is 











interventions and serve a much larger population. However, in the light of the population 
size (catchment area) and utilisation, these increases in resources are more than 
proportional to the population they serve. 
Table 5.8 Cost Estimates for Microscopy Diagnosis (in USD) 
Kabundi Namwiang Chongwe Makululu Total 
a.Catchment 31857 6140 15486 28951 82434 
b.Visits 3084 1975 3338 2063 10460 
Utilisation rate 0.10 0.32 0.22 0.07 0.16 
{b/a2 
Costs 
Personnel 18,946 2,977 27,095 6,328 55,347 
Capi tal (Routine) 1,160 1,279 4,197 501 7,136 
Capital 243 256 304 251 1,054 
(Laboratory) 
Diagnostic 3,423 2,192 3,705 2,290 11,611 
Technique 
Overheads 3,584 853 5,226 1,293 10,956 
Total Costs 27,355 7,558 40,528 10,663 86,103 
Unit cost per type of resource % 
Personnel 6.1 1.5 8.1 3.1 5.3 65% 

Capital (Routine) 0.4 0.6 1.3 0.2 0.7 9% 









Overheads 1.2 0.4 1.6 0.6 1.0 12% 

Cost per visit 8.9 3.8 12.1 5.2 8.2 100% 
The overall unit cost per visit was USD 8.2 (ranging from USD 3.8 to USD 12.1). 
However, controlling for the extra cost of diagnosis, the average unit cost is USD 7. This 
demonstrates that diagnosis related cost reach up to USD 1.2 per visit. The cost per visit 
was highest in Chongwe (rural) and lowest in Namwianga (rural). Except from diagnosis 
specific costs, there were considerable variations in unit costs across the resources. 
However the major source of cost variation was personnel. 
Table 5.9 below shows the major cost components of RDT diagnosis. Personnel costs 
accounted for 50% of the total costs. Kawama (urban) and Mukwela (rural) had the 












required by a health worker to prepare an RDT accounted 2% of total costs 
(assuming 5 minutes for preparation RDT sample). 
There were no laboratory capital but routine capital costs accounted 
for about 2% the total costs table 5.9). Compared to microscopy unit costs across 
seem to be more the unit cost capital 
costs was similar in all the four facilities. on the diagnostic technique was 
found to be high at an average of the total costs. Overhead costs were at 
5.9 Estimates RDT (in USD) 
MukwelaChalimbana Kawama Total 
a. Catchment 15638 6140 6596 6886 35260 
b. Visits 1187 874 1990 6685 
Utilisation rate (b/a) 0.08 O. OAO 0.29 0.19 
Diagnostic Technique 1,829 1 4,059 3,067 10,302 
Personnel 2,709 2,805 4,242 6,072 15828 
Personnel (extra time) 90 64 192 144 490 





Diagnostic Technique 1.5 1.5 1.5 1.5 1.5 33% 
Personnel 3.2 1.6 3.1 50% 
(extra time) 0.1 0.1 0.1 0.1 0.1 2% 
Capital (Routine) 0.1 0.1 0.1 0.1 0.1 2% 
Capital (Laboratory) 
Overheads 
shown in table unit cost of RDT diagnosis was USD 4.7 USD 
3.8 to USD 5.8). Excluding the extra costs related to RDT (USD 1.6) the 
unit cost to about USD 3.1. differences the unit cost patient among the RDT 












Personnel costs were clearly an important cost component among the three strategies. 
While clinical and RDT personnel costs were similar at about USD 2.3 - 2.4 per visit, 
microscopy personnel costs were found to be the highest at USD 5.3 per visit (with 
considerable variation across facilities) . Routine capital costs were also similar for 
clinical and RDT strategies but for microscopy they were 7 times higher. There was no 
cost associated to the diagnostic technique for clinical strategy, USD 1.2 for microscopy 
and higher for RDT at USD 1.6. Overheads were lowest in the clinical strategy and 
highest in the microscopy strategy. 
Overall, the unit cost per visit was USD 2.7, USD 8.2 and USD 4.7 for clinical, 
microscopy and RDT strategy respectively. Some of the differences in the costs may also 
be attributed to variations in the utilisation rates in facilities. 
5.4 Treatment Characteristics 
As demonstrated in this section it was established that malaria treatment patterns are not 
necessarily driven by diagnostic results. It was unlikely that physicians do not prescribe 
some malaria treatment, even if patients were considered or found negatives. Out of the 
12267 malaria cases found negative, only 17% (2113) did not receive any antimalarial, 
while 83% (9990) did receive antimalarial treatment. There was no provision to 
determine what the cases found negative received when they were affected by other (non­
malaria) conditions and returned to the clinic. This is because such details were not 












Figure 5.11 Treatment Characteristics 
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As shown in figure 5.11 above, the chance of a patient getting any of the three types of 
antimalarials depended upon the malaria status and the diagnostic strategy. Negative and 
positive malaria cases diagnosed by clinical methods were more likely to receive AL 
treatment than SP. However, in the microscopy and RDT strategies, cases diagnosed to 
be negative for malaria, were more likely to get SP than AL. Cases diagnosed positive by 
microscopy and RDT, were treated with AL more than SP. Across all the three strategies 
Quinine was prescribed more to the cases found positive than negative. Furthermore, a 
case clinically diagnosed to be negative (although these were very few) had less chance 
of being prescribed an antimalarial than a negative case diagnosed by either microscopy 
orRDT. 
Of all the cases visiting the facilities , 10% did not receive any treatment. Among this 
10% (2422), 2113 (87%) had been diagnosed malaria negative, 309 (13%) had been 
found to be positive for malaria . The reason for not treating some of the cases diagnosed 
malaria positive was not stated. However, this may be attributed to the cases being 
referred for further management at the next level of health care or a lack of drugs (stock 











5.5 Cost ofTreatment by Diagnostic Strategy 
The cost of antimalarial treatment was based on the number of patients treated and the 
type of antimalarial used. The recommended antimalarials for malaria in Zambia are AL, 
SP and Quinine (as described in section 2.3.2.1). In principle, healthcare workers are 
supposed to provide malaria treatment to those found positives (whatever the diagnostic 
method) 
The cost on other drugs (non-antimalarial treatment) was not considered in this study 
because such information was not systematically recorded. 
Table 5.10 below shows the estimated expenditure on antimalarial treatment in the 
clinical sites. "Number treated" refers to all the cases that were prescribed an antimalarial 
regardless of the test results (positive or negative). "Found positive" refers to the number 
who should have been treated if treatment were dependent upon the test result. The 
observed probability of being treated by SP, AL or Quinine when a case was found 
positive was used to estimate the cost of treating only those patients found positive. 
Table 5.10 Treatment Costs for Clinical Sites (USD) 
Kalilo Kalonda Chinyunyu Natuseko Total 
Visits 409 1020 1430 3661 6520 
Number treated 407 1020 l351 2842 5620 
Cost patients treated 614 1518 2379 4910 9422 
Av. unit cost observed 0.80 1.07 1.91 1.35 1.66 
Found positives 407 1020 1378 3024 5829 
Cost treating found positives 614 1518 2426 4871 9429 
Av. Unit cost found positive 1.51 1.49 1.76 1.61 1.62 












As shown in table 5.10 above, clinical diagnosis did not show any potential saving in 
antimalarial treatment, in fact the opposite occurs. This is because apart from the fact that 
nearly 100% of the cases are found positive, some cases found positives had not been 
treated in the first place (refers to section 5.4). In Natuseko, a saving of less than 1 % was 
observed where as in Chinyunyu 2% more was spent when only those found positive are 
treated as opposed to treating all the cases. The average unit cost of treatment was higher 
when only positives are treated as opposed to when both positives and negatives are 
treated. This difference in costs is related to the fact that AL, an expensive drug was more 
likely to be given to a positive case than SP. The average difference in the unit costs 
resulting from those treated and the scenario when only positives are treated was found to 
be small (USD 0.03). 
Table 5.11 below summarises the costs of antimalarial treatment in facilities where 
microscopy diagnosis of malaria was available. On average 56% (USD 7,118) of 
antimalarial treatments given to the patients could have been avoided if only the found 
positive were treated. As mentioned earlier, it is clear that most of the negative malaria 
cases are being given antimalarials. This seems to suggest that the treatment of patients 
may not be guided by microscopy results. Namwianga health centre showed the lowest 
savings. However, this is because most of the negative cases were given the cheaper SP 
while AL was mostly given to the found positive. Nevertheless, the fact that negative 
cases were prescribed a cheaper antimalarial (SP) than more expensive (AL) shows that 
in some way, a diagnostic tool helped to rationalise drug use. As explained earlier, the 
differences in costs for the two scenarios (observed treated and only found positives 
treated) is due to the differential of using AL more in the positive cases and SP was used 
more in the negative cases. The last column of figure 5.11 shows that the difference 
between the unit costs for the observed and scenario treatment costs (USD 0.16) was five 











Table 5.11 Treatment Costs for Microscopy Sites (USD) 
Kabundi Namwianga Chongwe Makululu Total 
Visits 3084 1975 3338 2063 10460 
Number treated 3075 1774 3325 1485 9659 
Cost patients treated 2459 1901 6344 2003 12708 
Av. unit cost observed 0.8 1.07 1.91 1.35 1.32 
Found positives 1563 771 1175 277 3786 
Cost treating found positive 1436 1523 2247 384 5590 
Av unit cost 0.92 1.98 1.91 1.39 1.48 
Potential savin~ 42% 20% 65% 81% 56% 
Table 5.12 below illustrates the treatment costs for RDT sites. The RDT facilities were 
observed to generate similar results to microscopy. Almost 60% of unnecessary 
antimalarial treatment could have been avoided if health workers prescribed antimalarials 
only to cases they found positive. The potential savings were very low in Mukwela 
because most negatives were treated with SP, which is cheaper than AL. On average, the 
difference in the unit cost of treatment between the observed and treating only positive 
scenario (USD 0.44) was relatively higher than both microscopy and clinical. As shown 
in figure 5.11 , this is attributed to the finding that in the RDT strategy, clinicians were 
more likely to use more AL for positive cases than either microscopy or clinical 
strategies. 
Table 5.12 Treatment Costs for RDT Sites (USO) 
Kasompe Mukwela Chalimbana Kawama Total 
Visits 1187 874 2634 1990 6685 
Number treated 934 536 2484 1576 5530 
Cost patients treated 1726 568 4504 1120 7918 
Av. Unit cost observed 1.85 1.06 1.81 0.71 1.43 
Found positives 287 261 960 213 1721 
Cost treating found positive 516 483 1842 384 3226 
A v unit cost found positive 1.87 1.85 1.92 1.80 1.87 











In the 8-month approximately USD 11, 803 was on non-
malaria cases in all the 12 facilities. However, this could be almost double if only 
the true malaria cases positive and false were considered 22, 886). 
Although it was observed that malaria treatment patterns were not entirely based on the 
test these were used to some extent in microscopy and RDT facilities. For 
example, SP (a cheaper drug) was systematically prescribed more to cases found negative 
while AL (the more expensive drug) was prescribed more to cases found positive (see 
5.1 The fact that 28% of patients in the clinical sites were treated with SP while 
65% were treated with AL also demonstrates that clinicians would discriminate among 
",,,t.pnt<: found positive. Some of them would be considered more likely to really have 
malaria and hence they get AL while others would be less to have it and 
SP. 
The overall cost of treatment per visit was estimated dividing the total cost of 
treatment by total visits for each the average cost of treatment per visit 
was 1.44 for clinical, 1.21 for microscopy and 1.18 for RDT strategy. This showed that 
RDT led to about USD 0.26 less than clinical and USD 0.03 less than microscopy on 
drug costs per patient visit. This may be because in the RDT clinicians 
were able to target treatment better than in clinical and microscopy 
In this section the costs on treatment associated with the inaccuracy of the different 
-'-,b"'-'~'~ methods is assessed. The cost on antimalarials to false positives was 
estimated using the number of false positives estimated for all the facilities and stratified 
by tool. Additionally, the mean unit cost per treatment was found using the 
observed 1J"-1ua.UUH",i> that a person found positive receive either drug (none, AL or 
quinine) under each diagnosis strategy (see section 5.4). The unit costs per drugs are 
those described in table 4.6 (in the methods section). Thus, the total cost per false positive 












TCFP = FP XL
4 
prob" x UnitCostTretament" (1) 
(/=1 
Where, 
TCFP = Total cost of false positives 
FP = Number of false positives 
Probd = The probability of treating a positive case with drug 'd ' 
UnitCostTretamentd = Unit cost of drug 'd' 
The mean cost per false positive per each diagnostic method was: 
CFP (Clinical) = 0.0339*0 + 0.3401 *0.18 + 0.6096*2.45 + 0.0164*0 .84 = 1.57 
CFP (microscopy) = 0.0195*0 + 0.3579*0.18 + 0.5784*2.45 + 0.0441 *0.84 = 1.52 
CFP (RDTs) = 0.0059*0 + 0.2129*0.18 + 0.7564*2.45 + 0.0248*0.84 = 1.91 
Similarly the cost of false negatives was estimated using the probabilities of treating a 
case found negative with antimalarials as follows : 
CFN (Clinical) = 0.5676*0 + 0.1675*0.18 + 0.2509*2.45 + 0.0141 *0.84 = 0.66 
CFN (microscopy) = 0.0728*0 + 0.5398*0.18 + 0.3771 *2.45 + 0.1013*0.84 = 1.11 
CFN (RDTs) = 0.1533*0 + 0.4321 *0.18 + 0.3666*2.45 + 0.0480*0.84 = 1.02 
Although the cost of non-antimalarial drugs would have been most appropriate to indicate 
the cost of false negatives, as stated earlier, the prescription of non-antimalarials drugs 
was not recorded. On the other hand, as demonstrated earlier even cases found negative 
were given antimalarials. In this case then it is expected that even if some cases were 
missed at diagnosis, treatment was given to them. 
The total cost of false positives per month was highest in the clinical strategy and lowest 
in the RDT strategy as shown in table 5.13 below. These results are influenced by unit 
cost and number of false positive per strategy (which in tum depend upon utilisation). 
That is why the expected cost per person diagnosed is also included for comparison (see 
last column table 5.13). The unit cost per false positive visit was highest in the clinical 











Number Probability Unit Cost! Cost Cost per Expected cost 
(a) of this person 8-Month month per visit 
diagnosis with this (a)x(c) (b)x(c) 
False positives 
Clinical 4875 0.75 1.57 7654 957 1.17 
1972 0.19 1.52 2997 375 0.29 
RDT 546 0.08 1.91 1043 130 0.16 
False negatives 
Clinical 93 0.014 0.66 61 8 0.01 
Microscopy 185 0.018 1.11 205 26 0.02 
RDT 58 0.01 1.02 7 
The cost of false was almost similar among the three ctr<.t"cY>PC as shown in 
table 5.13 above. This is because false negatives are mostly treated with SP. 
the overall cost of false positive (misdiagnosis) for the 8 months period (in 12 
was estimated to be USD 11, 694. in other contexts, where health workers 
treat based on the u"" ....'u,,.'v it would be lmln",'T;!"t to evaluate the other 
malaria) costs of false 
In order to a overview of the cost and outcomes, various unit costs 
were calculated per This is mainly due to the fact that, as demonstrated in 
section the actual treatment costs are not in line with the malaria test results. 
Therefore, the cost per case U'~'EY'U~'"'' (total cost of diagnosis/visits) was estimated using 
the total cost while excluding treatment costs. Then later, when estimating the cost per 
case correctly diagnosed, treatment costs were included in the total costs. In order to 
show the difference between treating all (as observed in the and only cases 
that are found positive by the strategy, the treatment costs were split into 
treatment costs 'All' (d) and treatment costs 'only treated' (e). Thus the 












Table 5.14 below shows the costs and cost effectiveness ratios for the three strategies. 
The average cost per patient undergoing malaria diagnosis was found to be lowest in the 
clinical strategy (USD 2.7). The cost of microscopy was three times the cost of clinical 
diagnosis and twice the cost of the RDT strategy per patient diagnosed. 
Table 5.14 Costs and Cost-Effectiveness Ratios 
Clinical Microscopy RDT 
a.Visits 6520 10460 6685 
Diagnosis Costs 
b. Cost of Diagnosis (prior treatment) 17,864 86,103 31,508 
c. Cost/I!..atient diagnosed (b/a2 2.7 8.2 4.7 
Treatment Costs 
d. Treatment costs (All treated)* 9,422 12,708 7,918 
e. Treatment costs (Onli: Qositive treated2** 9,429 5,590 3,226 
Total Costs 
f. Total cost (b+d)* 27,286 98,811 39,426 
g. Total cost (b +e)** 27,293 91,693 34,734 
h.Cost/patient diagnosed and treated (f/a)* 4.2 9.4 5.9 
i.Cost/Qatient diagnosed and treated (g/a2** 4.2 8.8 5.2 
Total Effectiveness 
j . Number of cases correctly diagnosed 1598 8303 6082 
k. ProQortion of cases correctli: diagnosed U/a2 0.25 0.79 0.91 
Average Cost Effectiveness Ratios (ACER) 
I. Total cost/cases correctly diagnosed (f/j) * 







* Scenario treating all as observed in the study 
** Scenario where only cases found positive are treated 
The potential savings on treatment if only cases found positive are treated were zero for 
clinical, 56% for microscopy and 59% for RDT strategy respectively. This shows that 
using clinical diagnosis may not lead to cost savings on treatment, while using RDT 













As mentioned the effectiveness measure for each '"M,"~.J'W stnlte~tv was defined 
as the number of cases and the 
proportion of cases diagnosed ([true visits). This 
distinction was done to estimate ACER (where the number of cases are needed) and 
ICER the proportion is Clinical was least effective 
while RDT was the most effective (0.91) at correctly cases as shown in table 
5.14 above. 
The average cost per patient diagnosed and treated was highest in the microscopy 
<:fT"t"cn, (USD 9.4) and lowest in the clinical strategy (USD 4.2) (see row h). However, 
the cost per patient diagnosed and treated is higher under current treatment practices (row 
h) than in a scenario where only found positives were treated (row 1), except for clinical 
diagnosis were it is the same. Note that in this the difference between clinical 
and RDTs diagnosis was above one dollar per visit. 
The ACER per case correctly VLUl',nv"".u was in the clinical followed 
rnl,rr"<:"'(1,nV and least in the RDT str<tte~~y the two situations 
described above as observed and treatment if only found are 
the ACER under the observed treatment (row I) was than when only cases 
found positive are treated (row except for the clinical <:tro,tpo"l' 
Incremental among the was conducted in order to evaluate the 
additional cost of cases correctly The in costs and 
effectiveness were calculated for from the least cost effective (clinical) to either 
microscopy or RDT. Given the differences in the number of patients seen by each 
cfT~,tpOr\l cost and effect have been estimated per patient. Hence, as shown in table 5.15 
below, the clinical strategy was used as baseline. 
Thus, when considering only costs, the incremental cost required per additional 
case correctly diagnosed was found to be lower for RDT (USD 3) than (USD 











and Johannesson 1999), Now when the incremental cost per additional case 
con-ectly diagnosed and treated, which was considered as the baseline ICER results (*), 
values reduced from USD 3 to USD 2.6 for RDT and from USD 10.2 to USD 9.6 for 
microscopy as shown in table 5.15 below. These decreases are due to the fact that, in 
comparison to clinical treatment with RDTs and Microscopy 
some savings on antimalarials. 
Table 5.15 Incremental Cost-Effectiveness Ratios 
Incremental Cost Effectiveness Ratios Clinical Microscopy RDT 
Cost/patient diagnosed (USD) 2.7 8,2 4.7 
5.5 2.0 
0.54 0.66 
------:------"'.1--0.,;,;;,,2­ 3.0-'-C:...=;;;..""'" _____--:-________ 
Cost/patient diagnosed and treated (USD)* 4.2 9.4 5.9 
Effectiveness per case 0.25 0.79 0.91 
Moving from clinical to either or RDTs 
Incremental costs 5.2 1.7 
Incremental effects 0.54 0.66 
with USD 6.5 per case coo'ectly diagnosed 
and an incremental cost of USD 3 over clinical strategy per additional case con-ectly 
diagnosed. On the other hand was dominated by RDTs (as this was more 
RDTs were found most cost effective 
rrlll'UI""" 
that if one 
to clinical _'_"""J~ is to be scaled up to the rest of the facilities this should be 
RDTs diagnosis. the cost of 
and less effective than These results 
this intervention was estimated in the 
four districts under study. The facilities in these districts already have basic 
infrastructure and human resource needed to implement the RDT for malaria lll""m".. 












measure and value the total additional resources required to implement RDT based on the 
establishments in each 
The main in the estimation of the costs of up the RDT is that 
this will be used for malaria in all the first level health facilities that exist in the 
district involved in the study lowest level of health care in Zambia). Thus, the few 
microscopy services available could be used for the diagnosis of other diseases. This is 
justified by the fact that the existing microscopy services are scarce and available only in 
main referral centres (inequitably distributed). Further, where these services are available, 
clinicians still do not antimalarials based on the microscopy results 
partly due to the lengthy period that it takes to get the laboratory results. Since the is 
to provide prompt and effective case management, RDT a faster, more 
practical and demonstrated more cost-effective way of ""'F.A"V""" malaria in first 
level health facilities. It should be noted that services would still 
be available at the levels of health care. 
The proportion of malaria related visits were estimated from the malaria 
utilisation rates in the respective district (see table 5.2). The incremental cost of the 
(USD 1.7) was used based on the incremental costs of and 
treatment for the RDT in relation to the clinical (see table 5.1 
Another cost of out the RDT ~Tr"<Tpo,,, one-week UQ':HlllJ<; programme for 
fi'ont line health workers to cater for theoretical and practical knowledge on the use of 
RDTs for malaria This should put a emphasis on 
treatment in line with the results. At least four 
U""'f-'U'"'' (2 nurses, 1 clinical officer, 1 EHT and per health facility 
would be trained (83 health facilities in total). All these cadres from each of the facilities 
in the study districts would be invited to participate in the training at one central level 
place. These trained workers would then in tum orient their fellow workers at their 
respective facilities. The cost of training includes cost of per diems and 












of such training was annualised at 5% for a of five years to an equivalent 
annual cost of USD 23, 487. Thus assuming that the "'''1'1,''''''1'1 gathered through the 
training will last 5 years. Table 5.16 below illustrates the potential costs of scaling up 
RDTs in the four districts. 
Population Rates Visits Cost a 8 months Month Cost 
(malaria) (malaria period 
Diagnostic Costs 
Chongwe 157664 0.24 37839 1.7 64,326.3 8,040.8 96,489.5 
Chingola 196685 0.09 17702 1.7 30,093.4 3,761.7 45,140.1 
Kabwe 196829 0.17 33461 1.7 56,883.7 10.5 
Kalomo 181379 0.23 41717 1.7 70,918.9 8,864.9 106,378.4 
Sub Total 732557 130,719 
Training (AEC) 23,487.0 
TOTAL 356,820.5 
AEC= Annual Equivalent Cost 
As shown in table 5.16 above, the annual scale up costs for RDTs in the four districts 
would be USD 356,820.5 leading to about 129,412 (0.66 x 196,079) additional cases 
correctly diagnosed per year. Out the total cost of scaling up the RDT strategy in the 
facilities, training accounted for 7%. The actual costs however would depend on 
availability of key personneL Further, the average costs reported here are likely to change 
with changes in expected visits. The incremental cost per case diagnosed and 
treated was found to be USD however, RDTs entails start up costs related 
to training. Thus the average incremental cost per case correctly "HU'5HVv",~ in the scale up 











One-way analysis was on in order to evaluate 
how changes assumptions affect the average and incremental cost effectiveness ratios 
for diagnostic test. The discount rates 0%, 3% and 6% were order to 
allow for comparison with other studies. The cost and might increase or 
to variations in demand and rates. use lower and 
higher estimates than the baseline values. The other estimates for sensitivity analysis 
include test accuracy, allocation factor and sensitivity of clinical ~'~"''''JU Personnel 
costs usually increase over time; hence a 10% increase in the cost of salaries was used as 
sensitivity value. Variations in the accuracy of clinical diagnosis were conducted as best 
case at 40% a lower accuracy for RDT at 80% was tested as worse case 
scenario. summary results of the analysis are contained in table 5.17. 
shown in table 5.17 below, undiscounted capital costs to a higher unit cost of 
diagnosis and consequently a all the three the 
degree of in costs depended on the proportion of capital costs found among the 
strategies compared. For ACER for by 30% 
while that for RDT strategy increased only by 18% proportion of capital costs was 
10% and microscopy and RDT respectively). RDT remained with lower 
cost per case correctly diagnosed. The RDT reduced by 12% (less by USD 0.3) 
while that for microscopy increased by 51 % (USD 4.9) when capital costs were 
undiscounted. 
The impact changing the discounting rate on the "'''~J..J.''- was similar hpic"">",,.., clinical 
and microscopy When a lower discount rate was applied (3%), there was a 
USD 0.10 of both the and microscopy However 
the for the RDT did not change with varying discount rates. be 
attributed to the observation that RDTs facilities had the lowest proportion of capital 
costs (2%) than clinical (4%) or microscopy (10%) facilities. However, among all 












correctly diagnosed and treated. The incremental cost per case correctly diagnosed did 
not change much in the RDT strategy because the proportion of capital costs was too low 
to cause meaningful impact. 
Table 5.17 Sensitivit~ Analysis Variables and Results 
Variable Baseline Sensitivity ACER ACER ACER lCER lCER 
value Clinical MicroscoE~ RDT Microscoe~ RDT 
Baseline results* 17.1 11.9 6.5 9.6 2.6 
Discount rate 5% 0% 22.3 17.0 7.7 14.5 2.3 
Discount rate 5% 3% 17.0 11.8 6.5 9.5 2.6 
Discount rate 5% 6% 17.1 11.9 6.5 9.6 2.6 
RDT cost USD 1.5 USD 0.5 17.1 11.9 5.4 9.6 1.1 
RDT cost USD 1.5 USD 2.00 17.1 11.9 7.1 9.6 3.5 
AL cost USD USD 1.5 15.4 11.4 6.1 9.7 2.8 
2.45 
AL cost USD USD 3.5 19.5 12.4 7.0 9.3 2.4 
2.45 
Sensitivity 100%, 80% 20.4 11.9 6.5 8.1 1.4 
clinical 90% 
Personnel costs 10% 18.2 12.6 6.7 10.2 2.6 
Increase 
Clinical 25% 40% 10.5 11.9 6.5 13.3 3.3 
Accuracy 
RDT accuracy 91% 80% 17.1 11.9 7.4 9.6 3.1 
Malaria 10% 21.5 14.5 8.4 11.7 3.6 
allocation 
factor 
Malaria -10% 13.1 9.4 4.7 8.0 1.7 
allocation 
factor 
*Baseline values for ACER and lCER refer to the scenario when all patients are diagnosed and 
treated as observed in the study as shown in table 5.14 and 5.15 respectively. 
When the cost of RDT was reduced to USD 0.5 per unit, the cost per case correctly 
diagnosed and treated by RDT reduced by 17% (in USD 1.0). On the contrary, if the cost 
of RDT rises to USD 2, the average cost per case correctly diagnosed and treated would 










reduced to USD 1.1 for the lower costs and increased to USD 3.5 when the RDT costs 
were increased. However, despite the changes in the unit cost, the RDT still dominates 
over the microscopy and clinical strategies. 
Variations in the cost of AL showed that at lower costs (USD1.5), the average cost per 
case correctly diagnosed reduced by 11 % (USD 1.88) for clinical, 5% (USD 0.4) for 
RDT and least of all 4% (USD 0.5) for microscopy. The opposite patterns were observed 
for increasing costs of AL to USD 3.5, where the increase in the ACER was found to be 
14% for clinical and 4% for both microscopy and RDT respectively. The largest impact 
was on clinical diagnosis because AL was used more for both cases found negative and 
positive whereas RDT and microscopy were likely to use AL more in the cases found 
positive than those found negative. The incremental cost per case correctly diagnosed and 
treated by microscopy and RDT increased by 1 % and 8% respectively when drug costs 
were reduced to USD 1.5. However, increasing drug costs to USD 3.5 resulted in a 3% 
and 5% increase in the lCER for microscopy and RDT respectively. 
lfthe sensitivity (true positives/total positives) of clinical diagnosis reduces to about 80%, 
it was observed that this would increase the average cost per case correctly diagnosed and 
treated by clinical strategy by 19% (USD 3.3). This is because at such low sensitivity, the 
number (and proportion) of cases correctly diagnosed reduces. This leads to a lower 
incremental cost of correctly diagnosing and treating cases by microscopy (USD 8.1) and 
RDT (USD 1.4). This is important especially for low malaria transmission areas where 
the sensitivity of clinical diagnosis is expected to be lower than in high transmission areas 
(Muhe et al 1999). 
Any increase in personnel costs would increase the ACER of all the three strategies. But 
the impact was less in the RDT strategy (3%) than either clinical (5%) or microscopy 
(6%). This is because the proportion of personnel costs out of the total costs were 51 %, 
65% and 83% for RDT, microscopy and clinical respectively. The increase in personnel 
costs did not impact on the lCER of RDTs against clinical diagnosis, but increased the 











If a training programme on clinical diagnoses were implemented, so that clinical 
diagnosis accuracy increases up to about 40%, this would reduce the average cost per 
case correctly diagnosed by 39% (USD 6.6). This would make clinical diagnosis to have 
a lower ACER than microscopy (at USD 10.50 versus USD 11.9 for microscopy). 
However, RDTs would still be the most cost effective intervention. Nevertheless, the 
feasibility of improving clinical accuracy to this level is not easily attainable. 
Assuming a lower accuracy of RDT diagnosis of 80%, (which could be argued due to 
poor training or quality assurance issues in current practise), would increase the average 
cost per case correctly diagnosed by RDT from USD 6.5 to USD 7.4. This also led to a 
19% increase in the incremental cost per case correctly diagnosed. Nevertheless, the RDT 
was still more cost effective. 
Variations in the malaria allocation factor on shared resources (mainly personnel) had 
demonstrable impact in the same direction on all the three strategies. Increasing the 
allocation factor by 10 units (x +10%) showed that the average cost per case correctly 
diagnosed increased by 26%, 22% and 29% for clinical, microscopy and RDT 
respectively. Conversely, reductions in the allocation factor reduced the ACER by similar 
proportions. The larger impact was on RDT and lowest in the microscopy. This is 
because in microscopy, laboratory related costs had a different allocation factor from 
other costs. Increasing the allocation factor increased the incremental cost of diagnosis to 
USD 11.7 (22% higher) for microscopy and USD 3.6 (38% higher) for RDT. 
Overall, the parameters that had the strongest effect on reducing RDT efficiency against 
the alternatives were increases in RDT and AL costs, reducing accuracy of the RDT, an 
increase in the malaria allocation factor (malaria visits as a proportion of all OPD visits 
and increasing personnel costs. On the other hand, the parameters that improve even 














This study has demonstrated the role of economic evaluation in malaria control. The cost 
effectiveness analysis of three available diagnosis methods for malaria (clinical, 
microscopy and RDTs) was conducted. The study was based on lower level health 
facilities in four districts in Zambia. Data on malaria visits, diagnosis strategies and 
treatment characteristics in the actual facility setting was used on, as is basis. Cost 
effectiveness was conducted from a providers' perspective. Effectiveness data was used 
from field evaluations on the ability of each strategy to correctly diagnose malaria related 
visits (accuracy). 
The cases correctly diagnosed were estimated based on the '2x2' table by applying the 
sensitivity of each test to the observed results so as to obtain true positives, false 
positives, false negatives and true negatives. Thus the number of cases correctly 
diagnosed was the sum of true positives and true negatives, while the proportion of true 
diagnoses out of all visits was referred to as the accuracy. The cost associated to malaria 
misdiagnosis was estimated in terms of the number of false positives and false negatives. 
The cost per patient diagnosed was least in the clinical and highest in the microscopy 
strategies. Clinical diagnosis was found to have the lowest diagnostic accuracy than 
either microscopy or RDT. Both groups of patients, found positives and negatives were 
being treated with an antimalarial, however, cases found negative received a cheaper drug 
in comparison to the cases found positive. The cost of correctly diagnosing cases was 
cheaper for RDT and highest in the clinical strategy. Changes in parameters and 
assumptions did not affect these results. RDTs remained the most cost effective strategy 
at correctly diagnosing cases for all tests performed, although increases and decreases in 











These findings are discussed in detail in the following sections. Other available studies 
relevant to cost effectiveness of malaria diagnosis were explored for any relationship to 
this study. The strengths and limitations of the study are outlined and policy 
recommendations suggested. 
6.1 Mean Cost per Patient Visit 
The fmdings in this study have shown that personnel costs are the major cost component 
for malaria diagnosis in all the facilities under study. However, personnel costs in relation 
to total costs by strategy accounted for 83%, 65% and 51 % for clinical, microscopy and 
RDTs respectively. Differences in the level of staffing in these facilities had a 
demonstrable impact on the unit cost per malaria patient visit. Overhead costs per patient 
visit were higher for the microscopy strategy than clinical and RDT strategies. This is 
much expected because microscopy services need extra utilities (water and electricity) 
apart from laboratory supplies while the RDT strategy needs extra recurrent costs for 
RDT and other supplies. On the other hand, laboratory related capital costs were unique 
to microscopy diagnosis alone (up to 1% of total costs of malaria diagnosis). 
As expected, clinical diagnosis was found to be cheaper per patient visit. This may be 
attributed to the lower resources required to implement this strategy. The unit cost for 
clinical diagnosis (USD 2.7) was three times lower than microscopy and almost two 
times lower than the cost of RDT diagnosis per patient. This is because RDT and 
microscopy require additional resources in order to confirm the presence of malaria 
infection. The unit cost per visit for clinical diagnosis of malaria did not vary much with 
setting, utilisation and underlying prevalence. The main source of variation was the 
personnel and overhead costs. Costs related to the diagnostic technology as a proportion 
of all malaria costs were higher in RDT sites than in microscopy sites. This may have 
implications for long-term sustainability of funding to implement RDTs. 
Clinical diagnosis of malaria was cheapest in the rural areas and most expensive in the 












rates between the two settings. This clear distinction in cost levels per patient diagnosed 
was not observed in the microscopy sites whose cost depended on resources as mentioned 
in the paragraph above. The cost was USD 2.18 for the most rural district (Kalomo) and 
USD 4.14 for the urban district (Chingola). The RDT strategy also showed a higher cost 
per patient diagnosed in the urban districts than in the rural districts. The lowest cost per 
patient was USD 4.30 in Chongwe (rural) and the highest being USD 6.89 in urban 
Chingola for the RDT strategy. Among the three strategies, the highest cost of diagnosis 
per patient was found in rural Chongwe district (USD 12.1 - microscopy). Malaria 
diagnosis was least expensive in rural Kalomo district (USD 1.6 - clinical). 
The differences in the personnel costs were related to the qualifications of the health 
worker at each facility. Some facilities had less professional health workers than needed 
hence resorted to hiring CDEs whose salaries were very low. This tended to reduce the 
cost per patient because personnel costs accounted for the highest proportion of the total 
costs. Urban health facilities had more health workers than rural facilities hence 
seemingly increasing the cost per patient diagnosed. 
6.2 Treatment Characteristics 
One major treatment feature was that, the diagnostic test result did not seem to influence 
the decision to either treat or not treat with an antimalarial. It was found that almost 87% 
of all facility visits were prescribed antimalarials regardless of the malaria test result. 
Thus antimalarials were given as much to cases found negative as the cases found 
positive. 
However, an interesting observation was that the test result influenced the type of 
antimalarial, which was prescribed to a patient. Given that the diagnostic strategies were 
not 100% accurate, health workers seem to be faced with two important decisions: 
Saving costs by treating only those found positive or reducing the risk of false negatives 
and its consequent complications by also treating the cases found negative. It is clear 











fonner. even in such a situation, there was a systematic of attempting to 
rationalise antimalarial use by prescribing a cheaper antimalarial to those who were less 
likely to have malaria (those found Those cases that were more to have 
malaria (found had a AL. Based on these 
observations; this does not the proposition that malaria diagnostic 
techniques do not treatment decision, 
This study demonstrated that there are cost (although moael'are on treatment 
associated to a diagnostic test. This in of the treatment ""ttp",,, behaviour 
discussed above. Clinical diagnosis had the rate of cost on treatment per visit at 
USD 1.44 while RDT had the lower USD 1.18. assuming a situation where a 
test result could strongly influence the decision to or not an 
antimalarial, microscopy and RDT diagnosis would have the potential of 56% and 
59% respectively on antimalarials. This applies to the scenario that only cases found 
positive are treated. It was also demonstrated the observed that 
clinical diagnosis does not offer any potential on costs. The differences in 
the levels of are mainly attributed to the variations in the accuracy of 
('r(1,,,(',",,, and and the observed treatment 
In Malawi, lonkman et al (1995) found that microscopy could lead to about 
USD14, 000 savings on annually in one hospital. In the Zambian context, it would 
be interesting to find out if the prescription trends found in the facilities (in this are 
similar in hospitals. This would provide an idea of the I)ULC;!!L!<U savings in antimalarials 
at that level of care. 
The ability of the available test in transfonning a low ..w~._ ..""t malaria probability into a 
post-test probability is also important in treatment decision-making. The nm;r-[c=s 
probability for a positive result on RDT (70%) was to allow the clinicians to 
treat a case. This would go a way in improving treatment 
UC'~!~'UlJ.-H,:a~u!~when with clinical and (53%). The post-











probability (like the one observed in microscopy and clinical) makes treatment decision 
more difficult and most likely would lead to treating even the cases found negative. 
6.3 Cost ofFalse Positives {or Each Diagnostic Strategy 
The effectiveness of a diagnostic test is measured by the ability of the test to reduce 
misdiagnosis . A good diagnostic test should differentiate the positive cases from the 
negative cases. This is important in helping to decide who should receive treatment for 
the disease in question. 
The cost of false positives is the result of the diagnostic inaccuracy together with 
treatment prescription behaviour. False positives arise when the test strategy has low 
specificity. The clinical strategy was found to have the highest number and proportion of 
false positives and consequently a high cost of treating them. The proportion of false 
positives was lowest in the RDT strategy (see table 5.3 to 5.5). Consequently, the average 
cost on false positives per visit was highest for clinical diagnosis at USD 1.17, followed 
by microscopy USD 0.29 and least of all in the RDT strategy at USD 0.16. Similarly, the 
highest cost of false positives per month was found in the clinical strategy (USD 957) 
while microscopy amounted to USD 375 and RDT USD 130 per month. It is important to 
state that the cost of false positives could have been higher if only AL had been used for 
malaria treatment. 
As reported in the literature (Amexo et aI2004), here clinical diagnosis is likely to lead to 
urmecessary treatments and consequently increase drug costs. The proportion of false 
positives was as high as 74% in the clinical diagnosis strategy. These findings are 
consistent with earlier reports that clinical diagnosis of malaria is responsible for 
overestimation of disease burden (Stephens et al 1999) and increase in drug expenditure 
(Amexo et al 2004). Further, in Thailand, the rate of false positives due to clinical 
diagnosis was found to be 68%, a figure similar to the estimates found in this study in 
Zambia. However, lower levels of false positives have been reported elsewhere. In 











in Uganda (Guthman et al 2002). Another study in Zambia, conducted during the peak 
malaria transmission season found that 49.3% cases clinically diagnosed were false 
positives (Ndhlovu et al 2004). 
Apart from the obvious effect on costs, irrational drug use may lead to stock outs of 
antimalarials at a time when they are most needed. The potential negative health effects 
this may have, cannot be underestimated. Furthermore, the increase in drug pressure in 
the population could increase the probability of drug resistance to ACTs developing early 
(Laxminarayan 2004, Bjorkman 2002). 
Microscopy diagnosis reported up to 18% false positives under routine conditions in this 
study. This is also explained by the fact that routine microscopy is less accurate than the 
gold standard expert microscopy. It is therefore important to observe here that in terms 
of reducing false positives (and in turn expenditure on unnecessary drugs) RDTs were 
more effective than microscopy and much more than clinical diagnosis. The RDTs' 
proportion of false positives was found to be lowest among the three strategies (8%). 
These findings are within the range of about 10% false positives expected on HRP-2 
based RDT (Shiff et al 1993). 
The cost of false positives could not be estimated in its true measure because the cost of 
non-antimalarial drugs was not consistently recorded. Thus it was not possible to estimate 
the cost of other drugs (non-anitmalarials). 
6.4 Cost ofFalse Negatives (or Each Diagnostic Method 
The proportion of false negatives was 1.1 %, 1.8% and 0.9% for clinical microscopy and 
RDT strategy respectively. False negatives have been said to be responsible for 
prolonged illness (Amexo et al 2004). This becomes more costly for both the health 
system and even more so for the patient. In terms of the health system, extra costs arise 











cost of patient management escalated due to inpatient costs of managing severe malaria. 
Thus a diagnostic strategy, which produces less false negatives, is preferred. 
Since most cases found negative were treated with SP, false negatives may be at risk of 
poor health outcomes. This is because SP has lower efficacy than AL (Chanda et al 2004) 
and so patients treated with SP may have a higher probability of returning to health 
facilities for further management. As clinical outcome was not the scope of this study we 
could not estimate such costs. A potential question for future research would be to assess 
cost effectiveness of diagnostic strategies for malaria using clinical outcome as 
effectiveness measure. Clinical outcome would be influenced not only by the test 
accuracy but also by the prompt and adequate treatment provided. 
Nonetheless, in this study, it was common practice for health workers to treat all fevers 
with antimalarials, including cases found negative for malaria. This helped to indirectly 
treat even the false negatives, which were missed at the point of diagnosis. Further, since 
almost all negatives received antimalarial treatment, the cost of treating false negatives 
with an antimalarial was not considered as a cost of misdiagnosis. 
6.5 Effectiveness ofDiagnostic Tests 
Out of a total of 23 600 malaria suspected visits, 48% were found positive across the 
three strategies. However, the proportion of cases found positive was 89%, 37% and 26% 
for clinical, microscopy and RDTs respectively. The overall proportion of cases correctly 
diagnosed was highest in the RDT strategy (91 %), followed by microscopy (79%) and 
least of all in the clinical strategy (25%). This is mainly due to the variations in the 
sensitivity and specificity of each of these tests under routine clinic conditions. When 
both the sensitivity and specificity are high, then the accuracy (proportion of cases 
correctly diagnosed) is expected to be high. For example, even though clinical diagnosis 
might have had a high sensitivity (as much as 100% in some facilities, the specificity was 











The cases correctly diagnosed were selected as outcome measures because retrospective 
data was collected among patients who were not actively followed up. This made it 
difficult to use a final outcome measure such as cases successfully treated after correct 
diagnosis . Thus within the realm of this study, it was not possible to estimate the link 
between correctly diagnosing a patient and the final clinical outcome. Such would be 
essential in assessing the true usefulness of the test. This is a potential area for further 
research. 
6.6 Cost Effectiveness ofthe Diagnostic Strategies 
The RDT was found to be cheaper at correctly diagnosing malaria (USD 6.5) than 
microscopy (USD 11.9) and clinical (USD 17. I) in routine outpatient clinics. This study 
is the fust in Zambia to demonstrate the cost effectiveness of malaria diagnosis in the era 
of ACTs as treatment for uncomplicated malaria. In different epidemiological settings 
and variable contexts, the clinical diagnosis of malaria was not a cost effective strategy 
for malaria diagnosis in Zambian districts if cases correctly diagnosed were to be 
maximised. The cost implication of using clinical malaria diagnosis is exacerbated by the 
high cost of antimalarials being used. For example, the average cost of treatment per 
person visit was USD 1.44, USD 1.2 I and USD I. I 8 for clinical, microscopy and RDTs 
respectively. This showed that using RDT was likely to lead to lower costs of drugs per 
patient visit than clinical and microscopy. 
The rate of false positives was too high in the clinical strategy (in comparison with the 
other 2 methods) and may playa role in deteriorating health status of the population who 
are misdiagnosed. These patients are administered with antimalarials when they should 
in fact be receiving the correct treatment for their true iIlness. This is even more relevant 
when prevalence is expected to be low. In the study the lowest and highest prevalence 
were 10.6% in Kabwe district and 26.3% in Kalomo district respectively. Thus the level 
of prior prevalence (around 20% on average) and the high proportion of cases found 












Microscopy malaria diagnosis in the peripheral health centres was less effective than 
expected (as compared by its assumed sensitivity). This may be largely due to the poor 
perfotmance by laboratory personnel in these facilities. These findings challenge the 
notion that microscopy is the gold standard for malaria diagnosis (Moody 2002, WHO 
2000c). Microscopy is only gold standard when perfotmed by expert microscopists 
(Hanscheid 2003). 
A study conducted by Rolland et al (2006) in a hypothetical epidemic situation found the 
cost per true malaria case detected by RDT was USD 19.87 while for clinical diagnosis it 
was USD 18.4 at 25% prevalence. Estimations at 50% and 75% prevalence level found 
RDTs to be less cost effective. Rolland et al used a hypothetical epidemic situation and a 
different outcome measure hence making comparisons with this study difficult. 
In a study by Buolombai et al (2003) in Thailand the cost effectiveness of microscopy 
was compared to two types of RDTs (OptiMAL and ICT) from a societal perspective. 
The study was conducted between April to October 2000 in remote non-microscope areas 
of Thailand. Microscopy was found to cost more per true Jalciparum positive case 
detected than the two RDTs (446.75 Baht vs 282.40 Baht and 343.56 Baht). At an 
exchange rate of about 37.56 Baht = 1 USD, this may be equivalent to about USD 11.90 
for microscopy, USD 7.52 for OptiMAL and USD 9.15 for ICT. Since this study is 
comparable in tetms of using a longer data collection period and actual malaria setting 
(except for the costing perspective), the findings may be more comparable to the 
Zambian situation than the Rolland et al study. However, none of these studies compared 
all the three interventions as conducted in this study. 
Thus when assessing the cost effectiveness of malaria diagnosis, differences in 
methodologies, and patient population characteristics are very important and need to be 
explored more. Additionally, this study found that health workers might have a role to 
play in modifying the potential effectiveness of a test through their actual practice when 
diagnosing malaria. Hence future research should explore these areas and the extent to 











The clinical strategy, which is the natural comparator for any other diagnostic method on 
malaria, was found to be less effective. Thus this strategy was used as baseline for 
incremental analysis, against which microscopy and RDT were evaluated. In incremental 
analysis, the cost per additional case correctly diagnosed was found to be 70% (USD 7) 
lower for RDT than microscopy. Thus demonstrate that it is more likely that policy 
makers would opt to implement RDTs since they require less additional resources but 
also yield more COITect diagnoses than microscopy, holding all other factors constant. 
Othnigue and colleagues have stated that, 
"At this stage and as the equipment and the necessary technical skills for microscopy­
based examination maybe difficult to scale up in the short run, rapid diagnostic tests 
based on the detection of Plasmodium antigens may be the most efficient approach to 
appropriately manage malaria as well as non-malaria cases. " (Othnigue et al 2006). 
6.7 Cost ofImplementing RDTs in Four Districts 
Since RDTs were found to be the most cost effective strategy, cost estimation was 
performed for scaling up RDTs to all the four districts in which the study took place. The 
incremental approach to scale up was used, based on the assumption that the available 
resources would allow for the roll out of RDTs in the lower level facilities. Of the total 
costs of scale up, RDTs accounted for a larger proportion (66%) while the remainder was 
for personnel costs and training. 
Thus RDTs themselves accounted for the larger proportion of implementing RDT 
strategy in the four districts. This is important because the cost of RDTs varies with the 
quantities used. Thus if this strategy is implemented in areas of higher prevalence and 
utilisation rates than the ones observed in this study, the cost of RDT would 
proportionally increase. 
The availability of RDTs on the market may determine the extent of scaling up this 
strategy. However, it has been reported that the increased demand for non-microscopic 











various species of Plasmodia (WHO 2000c). The resultant competition among suppliers 
would lead to reduction unit costs of RDTs and thus a lower incremental cost per case 
correctly diagnosed. 
The costs of supportive supeI'VlslOn and monitoring may be reduced if the RDT 
programme were integrated within other programmes. This would allow for savings as 
opposed to a vertical programme. About USD 356,821 is needed annually in order to 
scale up RDTs in the four district of the study. This would have an effect of 129,412 
additional cases correctly diagnosed. 
The health centres in which RDTs were being used were more under staffed than 
microscopy facilities. However, there are fewer lower level facilities, which are as well 
staffed as microscopy centres. Thus the cost of delivering RDTs based on the under 
staffed facilities is representative of the actual human resource constraints in lower level 
facilities in Zambia. Nevertheless it remains to be established whether the seemingly 
efficiency (lower cost per output) in these facilities do not lead to concerns related to 
quality of health care. This is because in these acilities, due to the human resource crisis, 
untrained CHWs and CDEs are part of the staff that attends to patients. This may 
compromise the quality of health care delivered. However, this was not established under 
the scope of this study and remains an area for further research. 
6.8 Sensitivity Analysis 
None of the parameters used in the sensitivity analysis changed the position of the RDT 
as the most cost effective strategy at correctly diagnosing malaria. However, some 
parameters increased the costs of cases correctly diagnosed, while others reduced the 
costs of case correctly diagnosed. 
Undiscounted capital costs led to an increase in the unit cost of diagnosis. The increase 
was higher in the microscopy (50%), followed by clinical (48%) and least in the RDT 












attributed to differences in the proportion of capital costs which were, 10%, 4% and 2% 
for microscopy, clinical and RDT strategies in that order. However, changes in the 
discount rates at 3% and 6% showed smal1 variations in the cost effectiveness ratio. This 
was because the proportion of capital costs was lower than other cost components such as 
personnel. More variations were observed in microscopy than clinical and RDTs. This is 
attributed to the observation that microscopy had the highest proportion of capital costs. 
Variations in the unit cost of RDTs would impact on the cost of correctly diagnosing 
cases. Should market prices reduce, this will definitely render the RDT strategy to be 
more technically efficient than either microscopy or clinical (as shown in table 5.17). 
However, increases in the unit cost of RDT will increase both the average cost per case 
correctly diagnosed and the incremental cost of correctly diagnosing cases by 9% and 
35% respectively. Thus price changes in the cost of an RDT will affect the amount of 
resources needed to implement this strategy. 
Cost of ACTs in the future may be expected to be lower than they are today, however, the 
countries' unstable exchange rates could lead to prices increasing or decreasing. Changes 
in the cost of AL would have a higher impact on clinical diagnosis, followed by RDTs 
and least in microscopy strategy. This is assuming that treatment patterns remain as 
observed in each strategy. A higher cost of AL increased the ACER of clinical diagnosis 
by 14%, RDT 8% and lowest in microscopy at 4%. Clinical diagnosis was more affected 
by changes in treatment cost because of higher rates of cases found positive and hence 
increased costs of drugs per visit. 
Advocating for lower costs of RDTs and ACT treatment is thus necessary so as to reduce 
the incremental cost of providing malaria diagnosis and treatment. This might help to 
encourage policy makers to adopt the new but more effective technologies in malaria 
control. 
The accuracy of a diagnostic test detennines the resultant cost per case correctly 












diagnosing malaria cases. When the accuracy was asswned at 40%, the ACER was USD 
10.50. However, even at this plausible higher estimate, RDTs and microscopy were 
cheaper at correctly diagnosing cases. This showed that even though clinical diagnosis is 
widely practised, it is a very inefficient way of increasing cases correctly diagnosed. 
A 10% increase in personnel costs increased the cost per case correctly diagnosed by 5% 
in clinical, 6% in microscopy and 3% in RDT. Microscopy was most affected because 
these sites had more personnel than any other sites (with the exception of rural 
Namwianga). This also shows that the unit cost of malaria diagnosis observed in this 
study may be related to the low staffing levels in most of the facilities. In areas where 
human resource capacity is higher, the cost of malaria diagnosis and treatment should be 
expected to be higher than that observed in this study. 
The malaria OPD equivalent (malaria related visit as proportion of all visits) was used as 
a major allocation factor for shared costs. Any increase in the allocation factor was seen 
to increase the ACER for all the three strategies. When the allocation factor was 
increased in ten perceptual points, the ACER increased more on RDT (29%) than clinical 
(26%) and microscopy (22%). Similar proportions of reduction were observed when for a 
decrease of ten perceptual points in the allocation factor. Thus if malaria OPD visits 
increase, the malaria share of the total facility costs would increase. It must be noticed 
here that in practice the allocation factor is correlated with other study parameters such as 
prevalence. Therefore this apparently high impact of the allocation needs to be treated 
with caution as it can be reduced when adjusting for a higher prevalence rate . 
In view of the changes in asswnptions and parameters discussed above, RDTs are more 
cost effective at correctly diagnosing malaria cases than microscopy and clinical 
diagnosis. All changes in asswnptions and parameters only impacted the cost of the 











6.9 Strengths and Limitatiolls ofthe Study 
6.9.1 Strengths 
A major strength of this study is that it was conducted within the actual malaria context 
using field-based data in a malarious population. This helped to incorporate actual 
practice unlike experimental studies, which may not apply to routine practice. Most 
studies, which have been conducted, based on hypothetical patient populations and 
settings miss the dynamics observed in this study. Even if such data is useful, but the 
application of the findings to a true set up may be limited. 
The observation period was long enough to account for seasonal variations. The study 
was carried out over 8 months between March and November 2005 . This allowed 
capturing both the high and low malaria transmission seasons. Malaria transmission in 
Zambia varies by season and this affects the expected patient visits and the prevalence of 
malaria at OPD. 
Furthermore, the study used a very large sample size of about 23 600 participants, 12 
facilities and four districts. The study districts had variable confirmed malaria prevalence 
ranging from 10.5% to 26%. Both rural and urban facilities were captured for each 
strategy. Thus the settings of the sample encompasses geographical and malaria 
epidemiology variations. These variations in the study sites offer an understanding into 
how facility utilisation, staffing levels, capital endowment and other capacities affect the 
cost of malaria diagnosis . 
The costing of the facilities was comprehensive as all the inputs required for malaria 
diagnosis were estimated in each facility. Costs were categorised into personnel, capital 
and overheads. This was measured according to the way they were used whether it is 
diagnostic technique related costs , patient screening or treatment. A discount rate of 5% 











The study also looked at all the possible outcomes of a diagnostic test as opposed to just 
focussing on the positive malaria cases. Thus the outcome measure considered both the 
true positive and true negatives, as these were the correct diagnoses while false positive 
and false negatives were misdiagnoses. 
The ability to conduct sensitivity analysis on variables used in the estimations of costs 
and effects provided insights into how the study findings would change across other 
settings and contexts. This not only helped to show the robustness of the results but also 
showed how costs of malaria diagnosis may vary depending on the prevailing situation in 
an area being considered. 
The leER for scaling up RDTs can be considered conservative as similar prescription 
practices were assumed, however if training proves to be effective at reducing over 
treatment with antimalarials, the incremental cost of rolling out the strategy should be 
lower. 
6.9.2 Limitations 
One of the main limitations of the study is that the outcome measure used in the analysis 
is an intermediate one. Thus it has been assumed that cases correctly diagnosed may be 
linked to improved fmal outcome (recovery from disease). However, the link between 
correctly diagnosing a case, an optimal clinical management of the patient and a 
satisfactory health outcome (after treatment) may be difficult to prove, without a close 
patient follow up . It was not possible within the context of this study to assess the 
differences in patient outcome after malaria diagnosis. This is an area for further 
research. 
The true cost of misdiagnosis in relation to other illnesses could not be fully documented 
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The use of facility registers may raise concerns with the reliability of the data due to 
potential errors in the data recording at facility level. However, the use of a three level 
supervision system (facility, district and national level) during the entire 8 months 
ensured completeness and consistency in the data collection process. 
Another limitation of the study arose from difficulties in defming the sensitivity of 
clinical diagnosis, as this can be very subjective. Further, clinical diagnosis does not 
allow for assessing the extent of missing patients who ideally should be suspected to have 
clinical malaria. Nevertheless, other studies conducted elsewhere, have shown similar 
sensitivity values as the estimates found in this study (Hozhabri et al 2002, Tarimo et al 
2001). 
In a study of this nature, gold standards (against which diagnostic results are measured) 
are impractical and potentially very expensive. Therefore the study relies on the 
assumptions on the sensitivity of different diagnostics techniques and prior prevalence of 
the districts sampled. Additionally, a strict inclusion criterion was applied to available 
studies to obtain estimates, which are similar to the Zambian setting. However, even 
though the best available estimates were used, there will always be some uncertainty 
about the selection of these values. 
The study facilities were not randomly assigned a diagnostic technique; hence differences 
in unit costs were not necessarily explained by differences in diagnostic strategies. That is 
why detailed tables were prepared and diagnostic and non-diagnostic costs were 
calculated separately. Nonetheless, the selected study sites were representative of the 
dynamics of the lower level facilities found in Zambia in terms of size, staffing levels and 
resource availability. 
Treatment practices (such as giving antimalarials to all patients) contribute to conceal the 
true cost-effectiveness values. On the other hand however, the study allows identifying a 
potential roll out challenge in this sense, which would have not come out if CEA had 












the available for malaria in Zambia, clinical was 
the cheapest per patient visit at USD microscopy was highest at USD 8.2 while RDT 
was at USD 4.7 per patient visit. However, considering the proportion of cases correctly 
diagnosed as the effectiveness indicator, clinical diagnosis was less effective at 25%, 
followed by microscopy at 79% and the highest cases diagnosed were by RDT 
at 91 %. Thus, even if the clinical was costing less per patient it was 
found to be less effective at correctly diagnosing cases. A result with clinical 
"""b""""" was a poor indicator of malaria infection (17%), moderate for microscopy 
(50%) and better for RDT (73%). This demonstrates that microscopy of malaria 
under routine conditions may not be the gold standard. 
A lower accuracy of a test resulted into a high proportion of false positives. 
The average rate of false was in the clinical strategy at 75%, 19% for 
microscopy and 8% for RDT. Consequently the cost of false per month was 
USD 957 for clinical, USD 375 for and USD 130 for RDT ~tr<,tpCf'\l 
It was estimated that the of false out of total visits was in the 
(1.8%), followed by clinical at 1.4% and lowest in the RDT at 1 %. 
False are not desirable in malaria diagnosis as such cases can develop 
severe malaria, which may be fatal. 
This study has shown that RDTs are the most cost effective method at correctly 
diagnosing malaria in lower level health facilities in Zambia when compared to clinical 
and This is relevant if cases correctly diagnosed are to 











The cost per case correctly diagnosed was USD 17.1 for clinical, USD 11.9 for 
microscopy and USD 6.5 for RDT from a providers' perspective. The incremental cost 
per case correctly diagnosed and treated was USD 2.6 for RDT compared to USD 9.6 for 
microscopy. Thus RDT would be much cheaper to scale up than microscopy. The 
findings were robust to changes in assumptions and parameters. The annual incremental 
cost of scaling up RDTs in the four districts involved in this research was estimated at 
about USD 356, 821. 
The cost of treatment per patient visit was lower for RDT (USD 1.18) than either 
microscopy (USD 1.21) or clinical (USD 1.44). This lower cost of treatment when using 
RDT shows that potentially RDT could lead to reductions on treatmOent costs. However, 
the amount of cost savings in drugs was limited by the treatment practices (both cases 
found positive and found negative were treated with an antimalarial). Noteworthy is the 
observation that both the ACER and lCER were lower for the scenario where the test is 
assumed to direct the decision to treat only cases found positive by microscopy and RDT 
strategies. This was however not true for clinical diagnosis. 
These findings could be relevant for transferability to low-income countries where 
malaria is endemic, AL is being used for first line treatment of malaria and diagnostic 
services are not readily available. 
7.2 Recommendations 
This study has endeavoured to illustrate various issues related to malaria diagnosis in the 
context of cost effectiveness. However, cost effectiveness of diagnoses alone may not be 
enough if other components of malaria case management are not addressed. Furthermore, 
there is need for more field-based evidence in the area of malaria diagnosis to encompass 












• 	 Improving malaria diagnosis can no longer be focussed on laboratory microscopy, 
but other non-microscopic methods such as RDTs should be explored. 
• 	 Microscopy should not be considered a gold standard for routine malaria 
diagnosis in lower level health facilities. This is because under daily practice in 
health centres, malaria microscopy had lower accuracy than it is purported to 
have. 
• 	 Undertaking qualitative studies to understand why health workers opt to treat 
most negative cases despite the test showing a negative result. This is especially 
important because for an RDT, the same person performs the test is the one who 
also prescribes treatment. 
• 	 Further research on the difference in health outcomes observed among the cases 
diagnosed clinically, microscopically or by RDT should be undertaken. This 
would contribute to the evaluation of the health impact of false positives and false 
negatives. 
• 	 An economic evaluation from a societal perspective would help to derive benefits 
to the patient when malaria is correctly diagnosed. 
• 	 The competency of malaria microscopists needs to be evaluated and judged 
against fully trained laboratory technologists. This will help to understand 
whether cost saving through lower personnel costs is worth the compromise on 
quality of laboratory results. 
• 	 The link between cases correctly diagnosed and final health improvement should 
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Appendix I. Data Collection Tools 
Cost and cost-effectiveness analysis of the available strategies for diagnosing 
malaria in outpatient clinics in Zambia. 





District catchment population: _________ 

Number ofhealth centres in district ______ 

Month being transcribed : __________ 

Malaria OPD attendance: --------------All disease OPD attendance: 
2. Cost Data 
i l. Capita) Costs (l ist) 
1.I Diagnostic related 
Quantity! Cost Life span 
1.2 Medical consultation related 
I 
1.3 Phannacy related 









Time spent on malaria related care 
I 
Salary plus fringe benefits . 
per month 
3. Supplies as used by each 




















i Reagents cupboard 
RDTs storage, etc 
Area occupied cost 
3.0 Malaria Facility Data 















5 Years and above Status 
+ve -ve Treatment 
! 
+ve = Declared malaria positive 











AnnualizaUon factors I 
Discount nile . 

1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17% 18% 19% 20% 

Il' 1 0.990 0.980 .0.971 0.962 0.952 0.943 0,935 0,926 0,917 0.909 0.901 0,893 0,885 0.871 0,870 0.662 0.855 0.647 0:840 0,833 
11 2 1.970 1.942 1.9131.886 1,859 1.833 1,BOB 1.783 1,759 1,736 1.713 1.690 1.668 1.647 1,626 1.605 1.585 1.566 1.547 1.528 
~ 3 2.941 2.884 2.829 2.775 2.723 2.673 2,624 2.577 2.531 2.487 2.444 2.402 2.361 2.322 2,283 2.246 2210 2.174 2.140 2.106 
: 4 3.902 3:BOB 3.717 3.630 3.546 3.465 3,387 3.312 3,240 3,170 3.102 3.037 2.974 2.914 2,855 2.798 2.743 2.690 2,639 2.589 
:: 5 4.853 4.713 4.580 4.452 4.329 4.212 4,100 3.993 3.890 3.791 3.696 3,605 3.517 3.433, 3.352 3.274 3.199 3:127 3.058 2.991 
E: 6 5.795 5.601 5.417 5.242 5.076 4.917 4.767 4.623 4.486 4.355 4.231 4.111 3.998 3.889 3.784 3,685 3.589 3,498.3.410 3.326 
iii' 7 6.728 6.472 6.230 6.002 5,786 5.582 5.389 5.206 5.033 4,868 4.712 4.564 4.423 4.288 4.160 4.039 3.9223.812 3.706 3.605 
5' 8 7.652 7.325 7.020 6.733 6.463 6.210 5.971 5,747 5.535 5.335 5.146 4.968 4.799 4.639 4.487 4.344 4.207 4.078 3.954 3.837 
': 9 8.566 8.162 7.876' 7.435 7.108 6.802 6.515 6,247 5.995 5.759 5.537 5.328 5.132 4,946 4.772 4.607 4.451 4.303 4,163 4.031 
9: 10 9.471 8.983 8.530 8.111 7.722 7.360 7,024 6.710 6.418 6.145 5,889 5.650 5.426 5.216 5.019 4.833 4.659 4.494 4.339 4,192 
.. 11 '10.368 9.787 9.253 8.760 8.306 7.887 7.499 7.139 6.805 6.495 6.207 5.938 5,687 5.453 5.234 5.029 4.836 4.656 4.486 4.327 
12 11.255 10.575,9.954 9.385·8.863 8.384 7.943 7.536 7.161 6.814 6.492 6.194 5.918 5.6605,421 5.197 4.9884.793 4,611 4,439 
13 12.134 11.348 10.635 9.986 9.394 8,853 8,358 7,904 1-487 7.103 6.750 6.424 6.122 5.842·5,583.5.342 5.118 4.910 4.715 4,533 
14 13.004 12.106 11.296 10.563 9,899 9.295 8,745 8.244 ],786 7.367 6.982 6.628 6.302 6,002 5,724 5.468 5.229 5.008 4.802 4.611 
15 13.865.12,84911.938 11.118 10.380 9.712 9.108 8.SS9 8,061 7.606 7.191 6.811 6.462 6.142 5.847 5.5755,3245.092 4.876 4.675 
16 14.718 13.578 12.561 11.652 10.838 10:106 9.447 8.851 8.313 7.824 7.379 6.974 6.604 6.265 5.954 5.668 5.405 5,162 '4.938 4,730 
17 15.562 14.292 13.166 12.166 11.274 10.477 9,763 9.122.8.544 8.022 7.549 7.120 6.729 6.373 6.047 5.749 5.475 5.222 4.990 4.775 
18 16.398 14,992 13.754 12.659 11.690 10.828 10.059 9.372 8.756 8~201 7.702 7.250 6.640 6.467 6.128 5.818 5.534 5.273 5.033 4.812 
19 17.226 15.678 14.324 13.134 12.085 11.156 10.336 9,604 8.950 8.365 7,839 7.366 6.938 6.SS0 6.198 5.877 5,584 5.316 5.Q70 4.843 
20 18.046 16.351 14.877 13.590 12.462 11.470 10.594 9.818 9.1298,514 7.963 7.469 7.025 6.623 6.259 5.929 5.628 5.353 5,101 4,870 
21 18.857 17.011 15.4,15 14.029 12.821 11.764 10.836 10.017 9.292 8.649 8,075 7.562 7,102 6.6B7 6.312 5.973 5,665 5.384 5.127 4.891 
22 19.660 17.658 15:937 f4.451 13.163 12.042 11.061 10.201 9.442 B.772 8.176 7.645 7.170 6.743 6,539 6.011 5.696 5.410 5.149 4.909 
23 20.456 lB.292 16.444 14.857 13.489 12.303 11.272 10.371 9.560 8.883 8.266 7.718 7.230 6.792 6,399 6.044 5.723 5.432 5,167 4.925 
24 21.243 1R914 16.936 15.247 13.799 12.550 11.469 10,529 9.707 8.985 8.34B 7.784 7.283 6.835 6.434 6.073 5.7465.451 5.182 4.ro7 
25 22.023 19.523 17.413 15.622 14.094 12.783 11.654 10,675 9,823 9.077 8.422 7.843 7.330 6.873 6.464 6.097 5.766 5.467 5.195 4,948 
26 22.795 20.121 17.877 15.983 14.375 13,003 11.826 10.810 9.929 9.161 8.488 7.896 7.372 6.906 6,491 6.118 5.783 5.480 5.206 4.956 
27 23,560 20.707 18.327 16.330 14.643 13,211 11.987 10.935 10.027 9.237 8.548 7,943 7.409 6.935 6.5146.136 5.798 5.492 5215 4.964 
28 24.316 2128118,764 16.663 14.898 13.406 12.137 11.051 10.1169.307 8.602 7.984 7.441 6.961 6.534 6.152 5,810 5.502 5.223 4.970 
29 25.066 21.844 19,18816.984 15.141 13.S9t 12.278 11.158 10.198 9.370 8.650 8.022 7.470 6.983 6.551 6.166 5,820 5.510 5.229 4.975 











CHNP AS002 - response to reviewers 
Response to Reviewers' Comments on Dissertation 




Literature review - In parts this reads as a summary of studies one-by-one, each 
with its own paragraph e.g. pages 22-25, 28-29, 33-36. A literature review should aim 
to do more than this. It should synthesise studies, showing where they are in 
agreement, and where they are not. This would have been facilitated by grouping 
studies by e.g. area, main malaria species, type of test etc. and describing general 
findings across studies, rather than the details of each one. 
Response: 






Parasite prevalence assumptions - I think the prevalence you refer to on page 57 
refers to the % of the community parasite positive. One would expect prevalence to be 
significantly higher among the sub-population presenting with fever. For example, in 
Tanzania the parasite prevalence of those presenting with fever at facilities was 
Response: 

Parasite prevalence assumptions: Although no change was made on the values used, 

details of why these data applies to facility-based malaria suspected cases were added 

in page 55 paragraph 3. 

Comment: 
Definition of Clinical Diagnosis - you need to clarify how this was done. Normally 
all fevers are considered "suspected malaria" and therefore clinically diagnosed. In 
which case you wouldn't expect some of the suspected malarias to be found negative 
by clinical diagnosis (Table 5.1 in one facility - Kabwe - this is particularly high). 
Can you clarify for Table 5.1 what the denominator is for % found negative and how 
clinical diagnosis was conducted. 
Response: Clarification of the definition of clinical diagnosis was emphasised III 
page 44 paragraph 2 . 
. Accuracy and consistency of results. 
Comment: 
• Fig 5.1 - total negative for clinical stated as 1702, but from Table 5.1 is 691. 
Similarly for most cells in table. 
Response: 
Fig 5.1 Total diagnosed clinically negative overall is more because some patients had 
more than one test perfonned such first the clinical diagnosis was done and thereafter 
microscopy was perfonned. However, the diagnostic test assigned to each facility was 
given dominance. Text and figures were amended to be consistent with table 5.1, 











CHNP AS002 - response to reviewers 
Comment: 
• 	 Page 72, para 1 - '74% seems wrong, surely 977/5829 =17%. Similarly for 1%, 
and for 19% in para 2 
Response: Page 72: revised as suggested. 
Comment: 
.l.- ~.- ~-
• 	 Page 85 - you appear to be using 2.45 as AL cost, but in Table 4.6 you give the 
average AL cost as 1.65. 
Response: Page 85: Corrected on page 61. usn 2.45 cost of antimalarials used 
(included storage and distribution costs). 1.65 was weighted average per dose before 
distribution and storage costs and should not have appeared in the table. Corrections 
have been made. 
Comment: 
• 	 rage lS~ - tne proportions getting UN with microscopy appear to have been 
reversed between the positives and negatives ie. Should be 0.1013 for false 
positives (although it is difficult to read from Fig 5.11, so maybe I'm mistaken) 
Response: Page 85; No changes because proportion getting QN with microscopy is 
correct as presented. 
Comment: 
• 	 .Page 87, Table 5.14 - line e for clinical of 9,380 does not seem to match 9,429 
from Table 5.10. Similarly line j of 1552 and 6081 do not seem to match Table 
5.6. In rows I and m denominator should be j not h. 
Response: Page 87: verified and corrections made 
Comment: 
• 	 Page 89, para 1 - you state these results are for "only positives treated" but they 
seem to match those for all treated in Table 5.14. 
• 	 Page 89, Table 5.15 - where do the incremental costs 4.6 and 1.1 come from ­
they don't seem to be derived from the cost/patient diagnosed and treated row. 
Response: Page 89, Table 5.14 figures and Table 5.15 , Table 5.6 corrections made 
and changes in ACER for clinical made to usn 17.1 as shown in table 5.14 and 
revised where applicable in the text. 
Comment: 
• 	 t'age Y:.:s, TatM:5.17 ~ why do you use as your baseline the results excluding drug 
costs? Surely it 'Would be more appropriate to include drugs as well? 
Response:~-Pag~' 93, "Table "5.17 the baseline results for ACER have drug costs 
included, please refer to Table 5.14 row f and g. However for ICER, the unit cost of 











CHNP AS002 - response to reviewers 
Comment: 
Clarify which findings are based on data and which on assumptions - you 
frequently make comments about diagnostic accuracy results e.g. Page 73, para 1, you 
state the diagnostic accuracy of microscopy in different facilities. This is only the 
assumed accuracy based on your assumptions about sensitivity which you assumed to 
be constant across facilities. In reality, average sensitivity may have been different, 
and sensitivity may have varied across facilities. I would start these sentences with a 
Response: Clarification on findings referring data or assumptions. An opening 
sentence has been inserted on page 71 to ensure that the reader is reminded on how 
cases correctly diagnosed (and hence accuracy) was calculated based on available 
literature on sensitivity for each diagnostic test as showed in table 4.6. 
Comment: 
Comparing costs and cost-effectiveness across diagnostic groups - by using the 

cost data from each group of facilities in your CEA you effectively assume that all the 

differences in cost between the groups can be attributed to the diagnostic method 

used. If you had a large and representative sample of facilities,allocated randomly to 

diagnostic method, this might be fair. In your case it is not, as it appears that e.g. 

microscopy was practiced in bigger facilities, with more qualified health workers, and 

as you note, utilisation varied. One needs to think in terms of "what would be the 

costs of introducing microscopy in the RDT and clinical facilities and vice versa. In 

comparing cost-effectiveness I therefore think it would be more appropriate to include 

only the costs specifically related to diagnosis, and to use an average across all 

facilities for the non-diagnostic costs. (you refer to Diagnosis costs in the analysis e.g. 

Table 5.14, but I think you mean all non-rlrug costs i.e. including consultation etc). 

Response: Issue pointed out in discussion (weaknesses): 
Comment: 
Costs of false positives and false negatives - I would have thought the appropriate 
analysis here would be to consider the cost of treating false positives compared to 
what they would have cost if they had been diagnosed accurately, and similarly for 
false negatives. This would be the "cost associated to malaria misdiagnosis" you refer 
to on page 96, para 2 (NB false negatives would actually have cost more if diagnosed 
appropriately). 
Response: Costs of false positives and false negatives. The primary objective of 

these calculations was to estimate the wastage on drugs due to wrong diagnosis. Thus, 

the ideal was to estimate the extent of otherwise "avoidable" expenditure on 

treatment. With this argument antimalarials given to false positives are relevant to 

consider as well as other drugs (non-malaria) given to false negatives patients. 

Unfortunately the latter information was not available and therefore this is recognised 















CHNP AS002 - response to reviewers 
Scope of Costs included - it is inconsistent to include a different scope of costs in the 

eEA and the scale up estimates (training and supervision included only in the latter). 

You could only do this if you could argue that these additional costs would not vary 

across diagnostic method. If these activities are required for implementation, and vary 

across methods, they should be included in the CEA costs. 

Response: Changed as suggested. The M&E and supervision costs were excluded 





Data reliability - you rely heavily on data from facility registers - these are 

notoriously incomplete and inaccurate do you have a feel for how reliable they were 

in this setting? 

Response: Data Reliability. Nonnally, facility registers are considered unreliable. 
However, in the context of the study, measures were put in place to assure data 
quality as described in the methods section. However, the issue has been added to 
limitation on page 111. 
Comment: 




Response: Other limitations have been identified as shown on page 109-110 
Comment: 
Table 2.1 - what does "% for every 25 births" mean? 
Response: Table 2.1 . Low birth weight occurrence clarified on page 10. 
Comment: 
Table 2.1 and Fig 2.1 - how is malaria prevalence defined in . the table - does this 
mean the prevalence of parasitaemia in the community? How are malaria cases 
defined in the figure - is this outpatient diagnoses? It's important to be specific about 
this as malaria is not the same as parasitaemia and (as you are clearly aware) malaria 
diagnoses are not all malaria. Similarly you need to define malaria incidence in Table 
4.1, and prevalence in Table 4.6 
Response: Malaria prevalence clarified. HMIS report include both confinned and 
unconfinned cases. Figure2.l malaria cases defined in the footnote. Table 4.1 and 4.6 
clarifications on definitions made. 
Comment: 
Page 22, para 3> - "Fever in the past 3 days" does not imply fever beginning at least 3 
days ago. Therefore a patient starting a f~vertQday.would still qualify as fever in the 
past 3 days. .. .. ... . 
. :. ", . . . 











CHNPAS002 - response to reviewers 
Comment: 
Page 36, para 4 - Goodman et al date is incorrect. 
Response: Page 36. Citation corrected to Goodman et al1999. 
Comment: 
Page 37, para 4 - specify that you mean IPTp i.e. in pregnancy, rather than in infants 
or children. 
Response: Page 37. IPT in pregnancy inserted. 
Comment: 
Page 38, para 2 - you attribute some of good CEA results for malaria treatment to the 
fact that treatment can also reduce transmission. However these preventive benefits 
are actually very rarely included in CEAs of treatment, and so won't account for the 
good results cited. 
Response: Page 38. Reduced transmission and thus lowers the malaria allocation 
factor leading to a lower cost effectiveness ratio. No changes made. 
Comment: 
Page 42, para 2 - defInition of allocative efficiency. It's a bit misleading defining this 
as looking at distributive patterns as it doesn't matter who receives the benefits. The 
key point is that it considers the allocation of resources across different interventions. 
Response: Page 42. Revised as suggested. 
Comment: 
Page 46, para 3, define CDE . 
. ' . ." .... .: .>. ..:"' .' 
Response: Page 46. CDE=Commissioned Daily Employee. 
Comment: 
i'lgure 4.1, thIrd row, would be better lahelled "suspected malaria" than "malaria 
confirmation". Alsou~clear why you have '~wast(lge of drugs" under "don't give
antimalarial". . . ... . 
Response: Figure 4.1 Corrections made 
Comment: 
Page 54 - does Taple 4,4 and text refer to initial suspected malaria or confirmed 

diagnoses? It's undear whether the data are comparable across facilities, or 

influenced by the diagnostic strategy used. . 

Response: Page 54. Table 4.4 refers to all malaria related visits (regardless of 
whether they come out positive or negative) reported at each facility regardless of 











CHNP AS002 response to reviewers 
Comment: 
Page 56 - what do you mean by a Bayesian Model? I don't see any use of Bayesian 
statistical methods in this study ... (similarly page 71) 
Response: Page 56. 2 x 2 Table used instead of Bayesian Model. However, the 
calculations used in the 2 x 2 originate from the Bayesian Theory not Bayesian 
Statistics. 
Comment: 
Page 56 - sensitivity for clinical diagnosis - you argue that 100% sensitivity can be 

assumed if all suspected malaria visits were classified as positive for malaria. 

However, you have no way of knowing if other true malaria cases never even got 

included in the suspected malaria group and were therefore false negatives. You have 

no way of assessing this, but it would be worth mentioning as a limitation. 

Response: Revised. The limitation aspect has been included. 
Comment: 
Page 63, para 1- by saying "Of these" you imply 47.46% of the 12,267 referred to in 
the previous sentence, which is not what you mean. 
Response: Page 63. Correct text inserted. 
Comment: 
Page 64, para 3 - you attribute the lower malaria~related visits in certain facilities to 
use of IRS - it could presumably also reflect underlying differences in disease 
patterns e.g. due to urban location. . . . 
Response: Page 64. Noted and added as possible explanation for the observations. 
Comment: 
Page 65, Table 5.2 - specifytime period for data. I think you mean rate of visits per 
population rather than % malaria visits. This is nonnaUy presented as a rate per 1000 
population, so for first row would be 78. .... 
Response: Page 65. Time period clarified and inserted in the table title. 
Comment: 
Page 66, para 1 - the cases do not start reducing in Sep. 
Response: Page 66. Clarified and corrected. 
Comment: 











CHNP AS002 - response to reviewers 




Page 83, line 7 - do you mean "higher than both microscopy and clinical diagnosis"? 
Response: Page 83: Corrected as suggested. 
Comment: 
Page 84, para 3~ line7 - should refer to Table 4.61 
Response: Page 84. corrected. 
Comment: 
Page 88, para 2 - check references to rows in Table 5.14 - don't seem to be correct. 
Response: Page 88. reviewed and corrected. 
Comment: 
Page 90, para 1, Hne 7/8 - on what basis do you argue. that clinicians did not follow 
microscopy results because ofthedelay? Yqualsotind they don't follow RDT results, 
which are quicker. 
Page 90, para 3~ do all health facilities really have this full complement of staff? If 
not, training costs will be lower, 
Response: sentence clarified on page 89 paragraph to include ... partly 
Response: Clarified in text on page 89. 
Comment: 
Page 94, line 2 - ROT strategy does not dominate clinical. Similarly page 95, para 1 
&2. 
Response: Page 94. Clarification inserted. 
Comment: 
Page 104, para 2 - is it possible to recalculate your results to make them comparable 
to Rolland et a1.? 
Response: Page 1 04. Methods used by Rolland et al differ from the ones used in this 
study, including the scenario (he used an epidemic situation and different outcome 
measure). No changes were made to avoid misinterpretation. 
Comment: 
Page 104, para 3 - Buolombai et al ref is not in bibliography. 











CHNP AS002 response to reviewers 
Comment: 
Page 112, para 3 - why are the results only relevant where microscopy is not available 
- surely you have shown that RDTs would be better even if microscopy were 
available? 
Response: Page 112. microscopy changed to diagnostic services for better 
understanding. The case for Zambia was what do we implement in areas where there 
is no microscopy already. 
Comment: 
There are at least 56 tYP9s in tbtthesis"-I suggest a final proof read befo~e re-
submission, 	 . .. . ... 
.. . /;.. ,',': ,,' 	 . . . . 
Response: Detected typos corrected and proof reading performed by author and a 
second person. . 
2. Response to Charlotte M Zikusooka Comments 
Comment: 
1. 	 Pg 3: Reference is made to 2001 data and the candidate uses the word 'currently'. 
Response: Pg 3. Currently deleted. 
Comment: 
2. 	 Pg 18, 26, 36: Whenever an author is quoted (witheX'act words in a qUotation marks), the 
reference must have a page number. .•.. . 
Response: Pg 18, 26, page numbers for quotations inserted. Page 36, quotation 
rephrased. 
Comment: 
3. 	 Pg 37: Whenever a 'Personal Communication' reference is used, both the names of the person 
and their designation have to be indicated. 
Response: Page 37. Name ofperson in personal communication indicated. 
Comment: 
4. 	 Pg 41 Table 3.3. I think more studies have been conducted on specificity and sensitivity of 
microscopy and RDTs. Hence more studies should be included for those categories. The 
candidate should make references to the following: 
Response: No changes: Page 41, Table 3.3 the studies included in this table have a 
specific inclusion criteria and specific tests so that only the results applicable to the 












CHNP AS002 response to reviewers 
5. 	 Pg 45: T~e discussion on economic evaluation methods is somewhat disjointed. E.g. in para 1, 
the candidate moves from 'discounting' to 'ICER' to 'sensitivity analysis' all in the same 
paragraph. 
Response: No changes: Page 45. The paragraph is a closing summary of the entire 
major steps in economic evaluation hence all concepts in one paragraph. 
Comment: 
6. Pg 54: Are the cases presented In Table 4.4 CONFIRMEO.malarla cases? . 
Response: Footnote inserted: Page 54. Table 4.4 refers to all malaria related visits 
(confmned and unconfirmed) in the facilities for the entire 2005 as per district 
information systems. 
Comment: 
7. 	 Pg 57: What is the basis for methods used in calculating health outcomes {I.e. False positive, 
True positives, False Negatives and True Negatives}. Are these methods used elsewhere in 
other literature? There is no reference made to such literature. 
Response: Page 57. The outcome measure in this case is based on screening 
methodology, which is in tum drawn from Bayesian theory. In other literature it is 
referred to as accuracy (true positives + true negatives). Please refer to articles in 
literature review. 
Comment: 
8. 	 Pg 67-70: What are the reasons for variations noted on Figures 5.5 and 5.77 Why is Kawama 
different from other study sites? The candidate should explore possible reasons for such 
differences. 
Response: Page 67-70. Kawama is located in an area where indoor residual spraying 
was conducted hence likely to record less malaria parasite positivity. 
Comment: 
9. 	 It is not clear whether the results presented under the classifications of True positives, False 
positives, etc ... (pg72 - 72) are calculated on the basis .of the formula presented on page 57 or 
whether it is reported based on tlie results fromthe "gold standard" (Le. expert microscopy). 
Response: Page 72. Formula for true positives, false positives, etc. refers to page 57 
in the methods section. Opening statement in the section 5.2 also clarifies the source 
of calculations. 
Comment: 
10. What does "priorprevalence"mean? 
Response: Prior prevalence- underlying parasite prevalence in the district as obtained 












CHNP AS002 - response to reviewers 
11. 	Pg 72-73: Explain the differences noted in different study areas. Eg. in Table 5.5 why is the 
accuracy of RDTs in Challmbama different from that in other study sites? 





12. 	Pg 76-77: Similarly, eXplain the variations in 'cost per visit'. E.g. see Table 5.8 




,~. In tiENERAL: the results could be better discussed. The current discussion of results is only.
descriptive: ./ . ... ..... . 
Response: Discussion reviewed and figures verified. 
Comment: 
5. Pg 87: Table 5.14 on rows 'I' and 'm', the formula should be f/j and g~ respectively. 
Response: Page 87. Rows I and m fonnula corrected. 
Detectable grammatical errors and spellings revised. 
10 
